
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="DB2B43CB9265E8533C43CB0033C12B27.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="ijms">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="International Journal of Molecular Sciences">
<meta name="citation_title" content="An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness">
<meta name="citation_author" content="Laura A Szafron">
<meta name="citation_author_institution" content="Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; laura.szafron@gmail.com">
<meta name="citation_author" content="Piotr Sobiczewski">
<meta name="citation_author_institution" content="Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland">
<meta name="citation_author" content="Agnieszka Dansonka-Mieszkowska">
<meta name="citation_author_institution" content="Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland">
<meta name="citation_author" content="Jolanta Kupryjanczyk">
<meta name="citation_author_institution" content="Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland">
<meta name="citation_author" content="Lukasz M Szafron">
<meta name="citation_author_institution" content="Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; laura.szafron@gmail.com">
<meta name="citation_publication_date" content="2024 Oct 10">
<meta name="citation_volume" content="25">
<meta name="citation_issue" content="20">
<meta name="citation_firstpage" content="10876">
<meta name="citation_doi" content="10.3390/ijms252010876">
<meta name="citation_pmid" content="39456660">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/pdf/ijms-25-10876.pdf">
<meta name="description" content="Borderline ovarian tumors (BOTS) are rare neoplasms of intermediate aggressiveness between cystadenomas and low-grade ovarian cancers (lgOvCa), which they share some molecular resemblances with. In contrast to the most frequent and well-described ...">
<meta name="og:title" content="An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Borderline ovarian tumors (BOTS) are rare neoplasms of intermediate aggressiveness between cystadenomas and low-grade ovarian cancers (lgOvCa), which they share some molecular resemblances with. In contrast to the most frequent and well-described ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11507582">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/ijms252010876"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/ijms-25-10876.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11507582%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11507582/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11507582/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-ijms.png" alt="International Journal of Molecular Sciences logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to International Journal of Molecular Sciences" title="Link to International Journal of Molecular Sciences" shape="default" href="http://www.mdpi.com/journal/ijms/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Int J Mol Sci</button></div>. 2024 Oct 10;25(20):10876. doi: <a href="https://doi.org/10.3390/ijms252010876" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/ijms252010876</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Int%20J%20Mol%20Sci%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Int%20J%20Mol%20Sci%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int%20J%20Mol%20Sci%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Int%20J%20Mol%20Sci%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Szafron%20LA%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Laura A Szafron</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Laura A Szafron</span></h3>
<div class="p">
<sup>1</sup>Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; laura.szafron@gmail.com</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Szafron%20LA%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura A Szafron</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sobiczewski%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Piotr Sobiczewski</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Piotr Sobiczewski</span></h3>
<div class="p">
<sup>2</sup>Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland</div>
<div>Resources, Data curation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sobiczewski%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Piotr Sobiczewski</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dansonka-Mieszkowska%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Agnieszka Dansonka-Mieszkowska</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Agnieszka Dansonka-Mieszkowska</span></h3>
<div class="p">
<sup>3</sup>Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland</div>
<div>Investigation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dansonka-Mieszkowska%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Agnieszka Dansonka-Mieszkowska</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kupryjanczyk%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jolanta Kupryjanczyk</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jolanta Kupryjanczyk</span></h3>
<div class="p">
<sup>4</sup>Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland</div>
<div>Formal analysis, Resources, Data curation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kupryjanczyk%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jolanta Kupryjanczyk</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Szafron%20LM%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Lukasz M Szafron</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Lukasz M Szafron</span></h3>
<div class="p">
<sup>1</sup>Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; laura.szafron@gmail.com</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Szafron%20LM%22%5BAuthor%5D" class="usa-link"><span class="name western">Lukasz M Szafron</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>
</div>
<div class="cg p">Editor: <span class="name western">Peter J K Kuppen</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-ijms-25-10876">
<sup>1</sup>Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; laura.szafron@gmail.com</div>
<div id="af2-ijms-25-10876">
<sup>2</sup>Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland</div>
<div id="af3-ijms-25-10876">
<sup>3</sup>Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland</div>
<div id="af4-ijms-25-10876">
<sup>4</sup>Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland</div>
<div class="author-notes p"><div class="fn" id="c1-ijms-25-10876">
<sup>*</sup><p class="display-inline">Correspondence: <span>lukszafron@gmail.com</span></p>
</div></div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Piotr Sobiczewski</span></strong>: <span class="role">Resources, Data curation, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Agnieszka Dansonka-Mieszkowska</span></strong>: <span class="role">Investigation, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Jolanta Kupryjanczyk</span></strong>: <span class="role">Formal analysis, Resources, Data curation, Writing – review &amp; editing</span>
</div>
<div class="p">
<strong class="contrib"><span class="name western">Peter J K Kuppen</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Jul 30; Revised 2024 Sep 12; Accepted 2024 Oct 7; Collection date 2024 Oct.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2024 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11507582  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39456660/" class="usa-link">39456660</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Borderline ovarian tumors (BOTS) are rare neoplasms of intermediate aggressiveness between cystadenomas and low-grade ovarian cancers (lgOvCa), which they share some molecular resemblances with. In contrast to the most frequent and well-described high-grade ovarian carcinomas (hgOvCa), the molecular background of BOTS and lgOvCa is less thoroughly characterized. Here, we aimed to analyze genetic variants in crucial tumor suppressors and oncogenes in BOTS (with or without the <em>BRAF</em> V600E mutation), lgOvCa, and hgOvCa in two gene panels using next-generation sequencing. Then, we verified the existence of selected polymorphisms by Sanger sequencing. Finally, Western blot analyses were carried out to check the impact of the selected polymorphisms on the expression of the corresponding proteins. Our study contributes to the molecular characterization of ovarian neoplasms, demonstrating divergent polymorphic patterns pointing to distinct signaling pathways engaged in their development. Certain mutations seem to play an important role in BOTS without the <em>BRAF</em> V600E variant (<em>KRAS</em>) and in lgOvCa (<em>KRAS</em> and <em>NRAS</em>), but not in hgOvCa. Additionally, based on multivariable regression analyses, potential biomarkers in BOTS (<em>PARP1</em>) and hgOvCa (<em>FANCI</em>, <em>BRCA2</em>, <em>TSC2</em>, <em>FANCF</em>) were identified. Noteworthy, for some of the analyzed genes, such as <em>FANCI</em>, <em>FANCD2</em>, and <em>FANCI</em>, <em>FANCF</em>, <em>TSC2</em>, the status of BRCA1/2 and TP53, respectively, turned out to be crucial. Our results shed new light on the similarities and differences in the polymorphic patterns between ovarian tumors of diverse aggressiveness. Furthermore, the biomarkers identified herein are of potential use as predictors of the prognosis and/or response to therapy.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> ovarian cancer, borderline ovarian tumor, DNA sequence variant, NGS, Western blot, <em>TP53</em>, <em>RAS</em>, <em>BRAF</em>, <em>BRCA1/2</em></p></section></section><section id="sec1-ijms-25-10876"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Ovarian carcinoma (OvCa) is a common and complex malignant disease with a generally poor outcome and an exceptionally high mortality worldwide [<a href="#B1-ijms-25-10876" class="usa-link" aria-describedby="B1-ijms-25-10876">1</a>]. There are two main types of OvCa: high-grade (hgOvCa) and low-grade (lgOvCa) ovarian carcinomas. The former is the most common type, characterized by extreme genomic instability, chromosomal rearrangements, and frequently mutated genes, especially those encoding tumor suppressor proteins, such as <em>TP53</em>, <em>BRCA1</em>, and <em>BRCA2</em> [<a href="#B2-ijms-25-10876" class="usa-link" aria-describedby="B2-ijms-25-10876">2</a>]. By contrast, lgOvCa is a rare ovarian tumor characterized by a younger age at diagnosis, relative chemoresistance, and prolonged survival compared to its high-grade counterpart. Additionally, lgOvCa do not bear or rarely have mutations in <em>TP53</em> and <em>BRCA1/2</em> [<a href="#B3-ijms-25-10876" class="usa-link" aria-describedby="B3-ijms-25-10876">3</a>,<a href="#B4-ijms-25-10876" class="usa-link" aria-describedby="B4-ijms-25-10876">4</a>], and they (especially those of the serous subtype) share molecular resemblances with borderline ovarian tumors (BOTS) [<a href="#B5-ijms-25-10876" class="usa-link" aria-describedby="B5-ijms-25-10876">5</a>]. BOTS are regarded as neoplasms that are less aggressive than invasive carcinomas. They are also a rare entity (about 15% of epithelial ovarian neoplasms) and have relatively low malignant potential. In contrast to OvCa, BOTS predominantly occur in women at a reproductive age, are usually diagnosed at a lower FIGO stage, and have better survival rates. Despite these advantages, BOTS are difficult to diagnose preoperatively by imaging methods because there are no specific criteria to distinguish them from their malignant counterparts with high confidence [<a href="#B6-ijms-25-10876" class="usa-link" aria-describedby="B6-ijms-25-10876">6</a>]. Additionally, following the complete removal of the tumor, even 20% of BOTS may recur. Most BOTS recur as borderline tumors; however, in about 30% of patients with peritoneal implants, OvCa develops [<a href="#B5-ijms-25-10876" class="usa-link" aria-describedby="B5-ijms-25-10876">5</a>,<a href="#B7-ijms-25-10876" class="usa-link" aria-describedby="B7-ijms-25-10876">7</a>,<a href="#B8-ijms-25-10876" class="usa-link" aria-describedby="B8-ijms-25-10876">8</a>]. In contrast to hgOvCa, in BOTS, mutations in <em>TP53</em> and <em>BRCA1/2</em> are rare [<a href="#B9-ijms-25-10876" class="usa-link" aria-describedby="B9-ijms-25-10876">9</a>,<a href="#B10-ijms-25-10876" class="usa-link" aria-describedby="B10-ijms-25-10876">10</a>,<a href="#B11-ijms-25-10876" class="usa-link" aria-describedby="B11-ijms-25-10876">11</a>], whereas the most frequently mutated genes are <em>BRAF</em> and <em>KRAS</em> (especially in BOTS of the serous subtype). Mutations in these genes are sometimes also found in serous lgOvCa, while, in patients with hgOvCa, their occurrence is rare [<a href="#B12-ijms-25-10876" class="usa-link" aria-describedby="B12-ijms-25-10876">12</a>,<a href="#B13-ijms-25-10876" class="usa-link" aria-describedby="B13-ijms-25-10876">13</a>]. In addition to <em>KRAS</em>, <em>BRAF</em>, <em>BRCA1/2</em>, and <em>TP53</em>, a few studies have also investigated the frequency of <em>PIK3CA</em>, <em>EGFR</em>, <em>CTNNB1</em>, <em>RAD51C</em>, <em>PALB2</em>, <em>CHEK2</em>, and <em>PTEN</em> mutations in BOTS compared to invasive ovarian carcinomas [<a href="#B14-ijms-25-10876" class="usa-link" aria-describedby="B14-ijms-25-10876">14</a>,<a href="#B15-ijms-25-10876" class="usa-link" aria-describedby="B15-ijms-25-10876">15</a>]. Nevertheless, data on the polymorphic status of tumor suppressors and oncogenes in BOTS remain scarce. OvCa are far better genetically characterized than BOTS. Still, there are discrepancies as to the clinical significance of some molecular markers that need to be dispelled.</p>
<p>Therefore, in BOTS without the <em>BRAF</em> V600E variant (here referred to as BOT), in BOTS harboring this genetic variant (BOT.V600E), and in lgOvCa and hgOvCa, we aimed to characterize the polymorphic status of 76 genes using two next-generation sequencing (NGS) gene panels. The first one comprised oncogenes and tumor suppressor genes involved in the development of hereditary ovarian cancer (41 genes) plus <em>CRNDE</em>, <em>IRX5</em>, and <em>CEBPA</em>. The second panel contained hot spots in genes frequently mutated in sporadic human cancers (37 genes), most of which were missing in the first gene panel. Except for the thorough examination of gene polymorphisms and their association with various clinicopathological parameters with the use of uni- and multivariable regression models, our workflow involved the confirmation of selected gene variants by Sanger sequencing, and also the verification of whether there is a correlation between the presence of the given polymorphism and the expression alterations of the corresponding protein. Hence, this work may contribute to a better understanding of the ovarian tumor molecular landscape and lay grounds for the discovery of new biomarkers.</p></section><section id="sec2-ijms-25-10876"><h2 class="pmc_sec_title">2. Results</h2>
<section id="sec2dot1-ijms-25-10876"><h3 class="pmc_sec_title">2.1. Distribution of Genetic Polymorphisms in Different Tumor Groups</h3>
<p>After the NGS and bioinformatic analyses, we obtained a list of genetic variants with a high or moderate impact on the corresponding protein’s structure and function. Genetic alterations with these impacts were either analyzed in combination or separately to determine whether the variants with distinct impacts exhibit concordant or discordant effects on the ovarian tumor outcome. Additionally, two questions need to be clarified. Firstly, in the 44-gene panel, one extra oncogene, the investigation of which was unintended, <em>KCNMB3</em> [<a href="#B16-ijms-25-10876" class="usa-link" aria-describedby="B16-ijms-25-10876">16</a>], was enriched. This was probably because its locus partially overlaps that of the <em>PIK3CA</em> gene, which was originally included in the panel and encoded by the opposite DNA strand. Similarly, in the hot-spot panel, one extra gene, <em>FBXW7-AS1</em>, was enriched, being an antisense transcript of the <em>FBXW7</em> gene [<a href="#B17-ijms-25-10876" class="usa-link" aria-describedby="B17-ijms-25-10876">17</a>], present in the hot-spot panel. Secondly, polymorphisms in the <em>CRNDE</em> gene (enriched in the 44-gene panel) were earlier described in another paper by our team [<a href="#B18-ijms-25-10876" class="usa-link" aria-describedby="B18-ijms-25-10876">18</a>], and therefore they will not be addressed in this article.</p>
<p>When using the 44-gene panel in the entire group of ovarian tumors, we discovered 85 unique, previously undescribed variants (71 new SNPs and 14 new non-SNPs). The list of all the detected variants is presented in a <a href="#app1-ijms-25-10876" class="usa-link">supplementary file named Supplement-variants.xlsx</a>. The cumulative frequency of all the detected genetic variants (SNPs and non-SNPs combined) in different groups of tumors is presented in <a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>A,B (variants with a high or moderate (A) or only a high (B) impact) and <a href="#app1-ijms-25-10876" class="usa-link">Figure S1A</a> (variants with a moderate impact only). In <a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>C–F and <a href="#app1-ijms-25-10876" class="usa-link">Figure S1C,E</a>, relevant box plots, depicting the overall frequency of SNP and non-SNP variants separately in different ovarian tumor groups, are shown. These box plots are additionally supplemented with detailed statistical tests. Furthermore, the mean counts of either SNP or non-SNP alterations per gene per tumor group are also presented in <a href="#app1-ijms-25-10876" class="usa-link">Figure S2A</a>–F. When considering all the variants together (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>A), the most frequently altered genes (the fraction of altered samples in at least one group &gt; 0.5) were <em>BRCA1</em>, <em>BRCA2</em>, <em>FANCA</em>, <em>SEM1</em>, and <em>TP53.</em> However, if only high-impact variants are considered (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>B), the highest frequencies of genetic alterations (&gt;0.3) were present in the <em>BRCA1</em> and <em>TP53</em> genes, and in the hgOvCa group only. By contrast, the number of SNPs with a high/moderate (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>C) or only a moderate (<a href="#app1-ijms-25-10876" class="usa-link">Figure S1C</a>) impact on a protein structure/function was significantly higher in the BOT without the <em>BRAF</em> V600E mutation compared to all the remaining tumor groups. Moreover, the same analysis revealed that the BOT.V600E tumors were characterized by a significantly lower number of SNPs than hgOvCa. Noteworthy, in hgOvCa, the number of high-impact genetic variants (either SNPs or non-SNPs) was significantly elevated compared to all the other tumor groups, except for SNPs with a high impact in the lgOvCa vs. hgOvCa comparison (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>D–F). Remarkably, the numbers of non-SNPs with only a moderate impact on a protein structure/function did not significantly differentiate any ovarian tumor groups (<a href="#app1-ijms-25-10876" class="usa-link">Figure S1E</a>), conceivably due to the low frequency of these variants (six such changes were found in only three genes, <em>ATRX</em>, <em>CHEK1</em>, and <em>PTEN</em> (<a href="#app1-ijms-25-10876" class="usa-link">Figure S2D</a>), exclusively in nine hgOvCa tumors (see <a href="#app1-ijms-25-10876" class="usa-link">Supplement-variants.xlsx</a>)).</p>
<figure class="fig xbox font-sm" id="ijms-25-10876-f001"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11507582_ijms-25-10876-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa32/11507582/ceab612b5982/ijms-25-10876-g001.jpg" loading="lazy" height="798" width="735" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-25-10876-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>SNP and non-SNP variants—44-gene panel. (<strong>A</strong>,<strong>B</strong>) The cumulative frequency of all variants per gene in each tumor group ((<strong>A</strong>)—variants with a high or moderate impact, (<strong>B</strong>)—only the variants with a high impact). (<strong>C</strong>–<strong>F</strong>) Box plots demonstrating differences in the numbers of genetic variants between the analyzed groups of tumors for SNPs ((<strong>C</strong>) a high or moderate impact, (<strong>D</strong>) only a high impact) and non-SNPs ((<strong>E</strong>) a high or moderate impact, (<strong>F</strong>) only a high impact). Each box plot is additionally supplemented with the Kruskal–Wallis rank sum test (showing whether there is any statistically significant difference between the analyzed sets of variants) and the Wilcoxon rank sum test with continuity correction (the post hoc test applied to determine which tumor groups differed from each other). NS: not significant. Group sizes: BOT: <em>n</em> = 53; BOT.V600E: <em>n</em> = 23; lgOvCa: <em>n</em> = 10; hgOvCa: <em>n</em> = 139.</p></figcaption></figure><p>For the hot-spot panel, we discovered 82 unique, not previously described genetic variants (75 new SNPs and 7 new non-SNPs). Their list can be found in <a href="#app1-ijms-25-10876" class="usa-link">Supplement-variants.xlsx</a>. The cumulative frequency of all the detected variants (SNPs and non-SNPs combined) in all the genes in every group of tumors is presented in <a href="#ijms-25-10876-f002" class="usa-link">Figure 2</a>A,B (variants with a high or moderate (A) or only a high (B) impact) and <a href="#app1-ijms-25-10876" class="usa-link">Figure S1B</a> (variants with a moderate impact only). In <a href="#ijms-25-10876-f002" class="usa-link">Figure 2</a>C–F and <a href="#app1-ijms-25-10876" class="usa-link">Figure S1D,F</a>, relevant box plots, depicting the overall frequency of SNP and non-SNP variants separately in different ovarian tumor groups, are shown. These box plots are additionally supplemented with detailed statistical tests. Furthermore, mean counts of either SNP or non-SNP alterations per gene per tumor group are also presented in <a href="#app1-ijms-25-10876" class="usa-link">Figure S2G</a>–L. When considering high and moderate variants together, and with SNPs and non-SNPs combined (<a href="#ijms-25-10876-f002" class="usa-link">Figure 2</a>A), the most frequently altered genes (the fraction of altered samples in at least one group &gt; 0.5) were <em>PTCH1</em> (altered in all tumor groups) and <em>TP53</em> (altered mainly in hgOvCa). Interestingly, genetic variants in the <em>BRCA1</em> gene were less frequently identified in the hot-spot panel than in the 44-gene panel. Nevertheless, if only the high-impact variants are considered, the mutational profiles of <em>BRCA1</em> and <em>TP53</em>, detected with both panels, were similar, revealing the high frequency of genetic alterations within these genes in OvCa, especially in hgOvCa (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>B and <a href="#ijms-25-10876-f002" class="usa-link">Figure 2</a>B). Notably, in the hot-spot panel, we also detected two variants in the <em>TP53</em> gene in one lgOvCa sample (chr17:g.7674921C&gt;A, p.Glu204Ter and chr17:g.7676218C&gt;A, p.Glu51Ter). Neither of these SNPs were found in the 44-gene panel, probably due to their low frequencies, equaling 11% and 14%, respectively. It needs to be mentioned here that, in our bioinformatic workflow, all sequence variants less frequent than 10% were filtered out to eliminate alterations resulting from DNA polymerase errors and those too rare to both elicit an evident clinical effect and be successfully validated by Sanger sequencing.</p>
<figure class="fig xbox font-sm" id="ijms-25-10876-f002"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11507582_ijms-25-10876-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa32/11507582/d8364eec6c05/ijms-25-10876-g002.jpg" loading="lazy" height="805" width="742" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-25-10876-f002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>SNP and non-SNP variants—hot-spot gene panel. (<strong>A</strong>,<strong>B</strong>) Cumulative frequency of all variants (SNPs and non-SNPs combined) per gene in each tumor group ((<strong>A</strong>)—variants with a high or moderate impact, (<strong>B</strong>)—only the variants with a high impact). (<strong>C</strong>–<strong>F</strong>) Box plots demonstrating differences in the numbers of genetic variants between the analyzed groups of tumors for SNPs ((<strong>C</strong>) a high or moderate impact, (<strong>D</strong>) only a high impact) and non-SNPs ((<strong>E</strong>) a high or moderate impact, (<strong>F</strong>) only a high impact). Each box plot is additionally supplemented with the Kruskal–Wallis rank sum test (showing whether there is any statistically significant difference between the analyzed sets of variants) and the Wilcoxon rank sum test with continuity correction (the post hoc test applied to determine which tumor groups differed from each other). NS: not significant. Group sizes: BOT: <em>n</em> = 53; BOT.V600E: <em>n</em> = 23; lgOvCa: <em>n</em> = 10; hgOvCa: <em>n</em> = 139.</p></figcaption></figure><p>When only SNPs are taken into account, the results for the hot-spot panel importantly differ from those obtained for the 44-gene panel with respect to the frequency of non-high-impact SNPs in the BOT group. In the hot-spot panel, the number of such SNPs in BOT was significantly lower than in both OvCa groups (<a href="#ijms-25-10876-f002" class="usa-link">Figure 2</a>C and <a href="#app1-ijms-25-10876" class="usa-link">Figure S1D</a>). By contrast, in the 44-gene panel, non-high-impact SNPs in BOT were much more abundant than in all the remaining tumor groups (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>C and <a href="#app1-ijms-25-10876" class="usa-link">Figure S1C</a>). Yet, this divergence disappeared when either high-impact SNPs or all non-SNPs were considered (<a href="#ijms-25-10876-f001" class="usa-link">Figure 1</a>D–F and <a href="#ijms-25-10876-f002" class="usa-link">Figure 2</a>D–F), revealing the increased frequency of genetic alterations in hgOvCa compared to BOTS in both panels.</p>
<p>All SNP and non-SNP variants per gene per sample were summed and binarized (at least one variant present vs. no alteration). The subsequent statistical analysis of this dataset, shown in <a href="#ijms-25-10876-t001" class="usa-link">Table 1</a>, revealed that <em>TP53</em> was the most differentiating gene between less aggressive tumors (BOT, BOT.V600E, and lgOvCa) and hgOvCa (in the latter, it was more frequently mutated), regardless of the gene panel and the variant impact. The only exception to this rule was found for high-impact alterations in the lgOvCa vs. hgOvCa comparison in the hot-spot panel, where no statistical significance was observed.</p>
<section class="tw xbox font-sm" id="ijms-25-10876-t001"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Genetic variants with a high or moderate impact significantly differentiating ovarian tumor groups, identified with two gene panels.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr><td colspan="7" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<strong>44-GENE PANEL</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Impact HIGH or MODERATE</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Group Comparison and <em>p</em>-Value</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gene</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. BOT.V600E</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>lgOvCa vs. hgOvCa</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TP53</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">5.67 × 10<sup>−31</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.23 × 10<sup>−18</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.8 × 10<sup>−9</sup> (↑hgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCB</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">9.71 × 10<sup>−3</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>SEM1</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.51 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.01 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCA</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.61 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCD2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.97 × 10<sup>−2</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.52 × 10<sup>−2</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.47 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>CHEK2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.04 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>MUTYH</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.44 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>RAD50</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.83 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Impact MODERATE</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Group Comparison and <em>p</em>-Value</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gene</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. BOT.V600E</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>lgOvCa vs. hgOvCa</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TP53</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.48 × 10<sup>−14</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">6.97 × 10<sup>−9</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.64 × 10<sup>−4</sup> (↑hgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA1</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.76 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCB</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">9.71 × 10<sup>−3</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>SEM1</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.51 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.01 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>MUTYH</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.8 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.83 × 10<sup>−3</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>CHEK2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">5.94 × 10<sup>−3</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCA</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.61 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCD2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.97 × 10<sup>−2</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.52 × 10<sup>−2</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>RAD50</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.83 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>PALB2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.31 × 10<sup>−2</sup> (↑BOT)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>ATM</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.62 × 10<sup>−2</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Impact HIGH</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Group Comparison and <em>p</em>-Value</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gene</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. BOT.V600E</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>lgOvCa vs. hgOvCa</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TP53</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.25 × 10<sup>−8</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.47 × 10<sup>−4</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.08 × 10<sup>−2</sup> (↑hgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>BRCA1</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.25 × 10<sup>−7</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.01 × 10<sup>−4</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4 × 10<sup>−2</sup> (↑hgOvCa)</td>
</tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>HOT-SPOT PANEL</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Impact HIGH or MODERATE</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Group Comparison and <em>p</em>-Value</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gene</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. BOT.V600E</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>lgOvCa vs. hgOvCa</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TP53</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.01 × 10<sup>−29</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">7.62 × 10<sup>−18</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.35 × 10<sup>−7</sup> (↑hgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRAF</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.52 × 10<sup>−16</sup> (↑BOT.V600E)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.08 × 10<sup>−8</sup> (↑BOT.V600E)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.08 × 10<sup>−23</sup> (↑BOT.V600E)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>NRAS</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.1 × 10<sup>−2</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.2 × 10<sup>−2</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.22 × 10<sup>−4</sup> (↑lgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA1</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.08 × 10<sup>−4</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FBXW7</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.67 × 10<sup>−2</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>KRAS</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.44 × 10<sup>−5</sup> (↑BOT)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.58 × 10<sup>−10</sup> (↑BOT)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.13 × 10<sup>−3</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.77 × 10<sup>−3</sup> (↑lgOvCa)</td>
</tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Impact MODERATE</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Group Comparison and <em>p</em>-Value</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gene</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. BOT.V600E</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>lgOvCa vs. hgOvCa</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TP53</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.27 × 10<sup>−15</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.66 × 10<sup>−9</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">8.26 × 10<sup>−5</sup> (↑hgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRAF</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.52 × 10<sup>−16</sup> (↑BOT.V600E)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.08 × 10<sup>−8</sup> (↑BOT.V600E)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.08 × 10<sup>−24</sup> (↑BOT.V600E)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>NRAS</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.1 × 10<sup>−2</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.2 × 10<sup>−2</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.22 × 10<sup>−4</sup> (↑lgOvCa)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>KRAS</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.44 × 10<sup>−5</sup> (↑BOT)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41 × 10<sup>−11</sup> (↑BOT)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.13 × 10<sup>−3</sup> (↑lgOvCa)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 × 10<sup>−3</sup> (↑lgOvCa)</td>
</tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Impact HIGH</strong>
</td></tr>
<tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Group Comparison and <em>p</em>-Value</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gene</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. BOT.V600E</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. lgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>BOT.V600E vs. hgOvCa</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>lgOvCa vs. hgOvCa</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TP53</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">5.84 × 10<sup>−9</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.35 × 10<sup>−4</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>BRCA1</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.98 × 10<sup>−3</sup> (↑hgOvCa)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/ijms-25-10876-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p><em>p</em>-values of the applicable (chi-squared or Fisher’s exact) test are included, followed by an arrow and the name of the group in which a given gene was more frequently altered (both written in brackets). In case of a lack of statistical significance, the corresponding cell is empty.</p></div></div></section><p>Two other genes worth mentioning here are <em>BRCA1</em> and <em>BRCA2</em>, since, in this study, their mutational profiles seemed to depend not only on the gene panel used but also on the impact that the genetic alterations had on the structure and function of the proteins encoded by these genes. In the 44-gene panel, both aforementioned genes turned out to be more frequently altered in BOT than in hgOvCa if moderate-impact variants were considered. This regularity also persisted if high-impact alterations in the <em>BRCA2</em> gene were included. By contrast, only high-impact <em>BRCA1</em> variants occurred much more frequently in hgOvCa than in all the other ovarian tumor groups (<a href="#ijms-25-10876-t001" class="usa-link">Table 1</a>). In the hot-spot panel, the <em>BRCA2</em> gene was not included, while the number of polymorphisms in <em>BRCA1</em> was significantly higher in hgOvCa than in BOT, irrespective of whether only high-impact or all genetic variants were taken into account.</p>
<p>In this study, <em>KRAS</em> was the gene in which high- or moderate-impact variants most strongly differentiated BOT from all the other tumor groups, except lgOvCa. In two other genes, involved in ubiquitination, <em>FANCB</em> and <em>SEM1</em>, moderate-impact variants were identified significantly more frequently in BOT than in OvCa (<em>SEM1</em>) or hgOvCa (<em>FANCB</em>). Of note, the variants in these two genes did not differentiate BOT from BOT.V600E. Moreover, from among 76 different genes investigated in the two panels in the present study, <em>BRAF</em> was the only one that was more frequently mutated in the BOT.V600E tumors compared to all the other groups.</p>
<p>Genetic changes in the <em>KRAS</em> gene occurred frequently not only in BOT but also in lgOvCa compared to BOT.V600E and hgOvCa. Apart from <em>KRAS</em>, variants in two other genes, <em>ATM</em> and <em>NRAS</em>, predominated in lgOvCa. ATM was more frequently altered in lgOvCa than in the BOT.V600E group, yet this regularity was confined to the moderate-impact variants only. As for <em>NRAS</em>, moderate-impact alterations in this gene prevailed in lgOvCa in comparison with the three remaining tumor groups.</p>
<p>For the confirmation of polymorphisms in the selected genes, we used gradient PCR combined with Sanger sequencing. With this technique, we managed to successfully verify one previously identified variant in the <em>TP53</em> gene (chr17:g.7670658_7670659insA, p.Lys351Ter) [<a href="#B19-ijms-25-10876" class="usa-link" aria-describedby="B19-ijms-25-10876">19</a>] and seven new variants (SNPs and non-SNPs) with either a moderate or high impact on a protein’s structure/function. The verification results and the detailed description of each analyzed polymorphism are presented in <a href="#app1-ijms-25-10876" class="usa-link">Figure S3</a>.</p></section><section id="sec2dot2-ijms-25-10876"><h3 class="pmc_sec_title">2.2. Regression Analyses</h3>
<p>Using the 44-gene panel, we identified that the genetic variants in <em>PARP1</em> were of prognostic value and had a significant impact on BOTS patients’ RFS (<a href="#ijms-25-10876-t002" class="usa-link">Table 2</a> and <a href="#ijms-25-10876-f003" class="usa-link">Figure 3</a>A–D). Notably, no genetic variants in the genes investigated in this study were identified as good predictors of the occurrence of microinvasions or implants within the tumor masses in BOTS. In hgOvCa, the only marker found to be predictive of response to chemotherapy were genetic variants in <em>BRCA2.</em> Polymorphisms in this gene positively affected both the CR and PS in patients with tumors without the TP53 protein accumulation, either treated with TP or irrespective of the chemotherapeutic regimen used (<a href="#ijms-25-10876-t002" class="usa-link">Table 2</a> and <a href="#ijms-25-10876-f003" class="usa-link">Figure 3</a>I). The genetic variants in <em>BRCA2</em> revealed their favorable prognostic value as well by decreasing the risk of death in the whole group of patients, in the subgroup treated with TP, and in patients with tumors without TP53 accumulation. The <em>FANCF</em> gene was discovered here as another marker of a good prognosis in hgOvCa, as its polymorphisms diminished the risk of death in the TP-treated patients with tumors lacking the TP53 accumulation. By contrast, in the same group of patients, the <em>FANCI</em> gene was identified as a negative prognostic factor, elevating the risk of relapse (<a href="#ijms-25-10876-t002" class="usa-link">Table 2</a> and <a href="#ijms-25-10876-f003" class="usa-link">Figure 3</a>E–H).</p>
<section class="tw xbox font-sm" id="ijms-25-10876-t002"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>The results of multivariable Cox and logistic regression analyses for the models with good discriminating capabilities (assessed based on their AUC values) that matched with corresponding univariable tests.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr><td colspan="3" align="center" valign="middle" style="border-top:solid thin" rowspan="1">
<strong>44-Gene Panel</strong>
</td></tr>
<tr><td colspan="3" align="center" valign="middle" style="border-top:solid thin" rowspan="1">
<strong>BOTS</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>RFS/relapse in the whole group of patients (full table)</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>
<span class="text-underline">PARP1</span>
</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">6.82 [1.584–29.39]</span>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">0.01</span>
</td>
</tr>
<tr><td colspan="3" align="center" valign="middle" rowspan="1">
<strong>hgOvCa</strong>
</td></tr>
<tr>
<td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<strong>DFS/relapse in the subgroup of patients treated with TP and without <em>TP53</em> accumulation in tumors</strong>
</td>
<td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>
<span class="text-underline">FANCI</span>
</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<span class="text-underline">40.02 [3.784–423.133]</span>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<span class="text-underline">0.0022</span>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<span class="text-underline">Residual tumor &lt;2 cm vs. no residual tumor (0 cm)</span>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<span class="text-underline">22.77 [2.061–251.608]</span>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<span class="text-underline">0.01</span>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">Residual tumor </span>
<span class="text-underline">≥</span>
<span class="text-underline">2 cm vs. no residual tumor (0 cm)</span>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">34.1 [2.547–456.619]</span>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">0.0077</span>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>CR in the subgroup of tumors without <em>TP53</em> accumulation</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>
<span class="text-underline">BRCA2</span>
</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">7.06 [1.328–37.581]</span>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<span class="text-underline">0.022</span>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OS/death in the whole group of patients (full table)</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.58 [0.399–0.85]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.005</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Residual tumor &lt;2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.85 [1.654–4.903]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.6 × 10<sup>−4</sup>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Residual tumor ≥2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.75 [2.058–6.821]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.55 × 10<sup>−5</sup>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OS/death in patients with tumors without TP53 accumulation</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.42 [0.204–0.865]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.019</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Residual tumor ≥2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.63 [1.348–15.883]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OS/death in the subgroup of patients treated with TP</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.53 [0.337–0.84]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.007</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Residual tumor &lt;2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.97 [1.616–5.471]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.6 × 10<sup>−4</sup>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Residual tumor ≥2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.94 [1.944–7.986]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 × 10<sup>−4</sup>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>CR in the subgroup of patients treated with TP and without TP53 accumulation in tumors</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.73 [1.047–43.239]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.045</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>PS in the subgroup of tumors without <em>TP53</em> accumulation</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.23 [1.509–44.836]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>PS in the subgroup of patients treated with TP and without TP53 accumulation in tumors</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>
<em>BRCA2</em>
</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.33 [1.251–55.476]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OS/death in the subgroup of patients treated with TP and without TP53 accumulation in tumors</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>FANCF</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.15 [0.024–0.976]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.047</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Residual tumor &lt;2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.69 [1.159–11.74]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.027</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Residual tumor ≥2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.75 [1.84–32.595]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td>
</tr>
<tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Hot-Spot Panel</strong>
</td></tr>
<tr><td colspan="3" align="center" valign="middle" rowspan="1">
<strong>hgOvCa</strong>
</td></tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>OS/death in the subgroup of patients treated with TP and with TP53 accumulation in tumors</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>HR [95% Cl]</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>p</em>
</strong>
<strong>-value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>
<em>TSC2</em>
</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.52 [1.191–5.329]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.016</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Residual tumor &lt;2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.86 [1.312–6.249]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.008</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Residual tumor ≥2 cm vs. no residual tumor (0 cm)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.61 [1.104–6.146]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/ijms-25-10876-t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn3"><p>The best models, the discriminating capabilities of which are shown in <a href="#ijms-25-10876-f003" class="usa-link">Figure 3</a>, are underlined. AUC values for each model are provided in a file named <a href="#app1-ijms-25-10876" class="usa-link">Supplement-matching regression.xlsx</a>. RFS—relapse-free survival; OS—overall survival; DFS—disease-free survival; TP—taxane/platinum chemotherapy; CR—complete remission; PS—platinum sensitivity; HR—hazard ratio; OR—odds ratio; CI—confidence interval.</p></div></div></section><figure class="fig xbox font-sm" id="ijms-25-10876-f003"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11507582_ijms-25-10876-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa32/11507582/717ef49e747b/ijms-25-10876-g003.jpg" loading="lazy" height="913" width="735" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-25-10876-f003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Cox and logistic regression analyses for selected genes. (<strong>A</strong>–<strong>H</strong>) Cox regression analysis results for the <em>PARP1</em> gene (RFS) in the whole BOTS group (<strong>A</strong>–<strong>D</strong>) and for the <em>FANCI</em> gene (DFS) in the subgroup of hgOvCa patients treated with the TP regimen and without <em>TP53</em> accumulation in their tumors (<strong>E</strong>–<strong>H</strong>). (<strong>I</strong>) Logistic regression analysis results for the <em>BRCA2</em> gene (CR) in the subgroup of hgOvCa patients without TP53 accumulation in their tumors. (<strong>A</strong>,<strong>B</strong>,<strong>E</strong>,<strong>F</strong>) AUC plots for uni- and multivariable Cox regression models obtained before (<strong>A</strong>,<strong>E</strong>) and after (<strong>B</strong>,<strong>F</strong>) a bootstrap-based cross-validation of the original dataset. The red dashed line indicates the same time point that was used to draw the time-dependent ROC curves (<strong>C</strong>,<strong>G</strong>). Optimal cutoff points for these ROC curves were calculated for the multivariable models based on the Youden index. Discrimination sensitivity and specificity values for cutoff points, determined for ROC curves in (<strong>C</strong>,<strong>G</strong>), are also provided. (<strong>D</strong>,<strong>H</strong>) Kaplan–Meier survival curves obtained for the patients divided into two categories (risk higher (high) or lower (low) than for the ROC curves’ (<strong>C</strong>,<strong>G</strong>) estimated cutoff point, based on the risk of relapse, calculated using the multivariable models. The Kaplan–Meier curves are supplemented with the results of the log-rank test as well. (<strong>I</strong>) ROC curves for uni- and multivariable logistic regression models. An optimal cutoff point for these ROC curves was calculated for the multivariable model based on the Youden index. Discrimination sensitivity and specificity values for this cutoff point are also provided. RFS—recurrence-free survival; DFS—disease-free survival; RT—residual tumor size; CR—complete remission; TP—taxane/platinum chemotherapy.</p></figcaption></figure><p>In the hot-spot panel, no genetic variants of prognostic or predictive importance were found for BOTS. For hgOvCa, we discovered a single adverse prognostic marker, <em>TSC2</em>. Genetic variants in this gene increased the risk of death in patients treated with the TP regimen, whose tumors exhibited the accumulation of the TP53 protein (<a href="#ijms-25-10876-t002" class="usa-link">Table 2</a>).</p>
<p>Of note, the regression analysis was not performed for lgOvCa patients due to the small size of this cohort (<em>n</em> = 10), making multivariable statistical inference impossible. Nevertheless, it is worth emphasizing here that in the randomization (chi-squared and Fisher’s exact) tests, described in <a href="#sec2dot1-ijms-25-10876" class="usa-link">Section 2.1</a>, we managed to obtain statistically significant results for comparisons involving lgOvCa, which proved that the statistical power of these tests was high enough despite the rarity of lgOvCa tumors in our experimental setup.</p></section><section id="sec2dot3-ijms-25-10876"><h3 class="pmc_sec_title">2.3. Assessment of Relationship between Selected Gene Polymorphisms and Expression of Corresponding Proteins</h3>
<p>To evaluate, on the protein level, the effects of the genetic alterations found in this study, we analyzed the expression of several proteins encoded by genes with SNP and non-SNP variants. The Western blot (WB) results are presented in <a href="#ijms-25-10876-f004" class="usa-link">Figure 4</a> and <a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>. We observed a lower or no signal on a membrane for non-SNP frameshift polymorphisms detected in the following: <em>NBN</em> (chr8:g.89971217_89971221del, p.Lys219AsnfsTer16; <a href="#ijms-25-10876-f004" class="usa-link">Figure 4</a>A); <em>CHEK2</em> (chr22:g.28695869del, p.Thr367MetfsTer15; <a href="#ijms-25-10876-f004" class="usa-link">Figure 4</a>C); and <em>TP53</em> (chr17:g.7674900dup, p.Thr211AsnfsTer5; chr17:g.7670686del, p.Arg342GlufsTer3; chr17:g.7674241del, p.Cys242AlafsTer5; chr17:g.7676078del, p.Pro98LeufsTer25; chr17:g.7676041_7676042insTTTC, p.Arg110GlufsTer40; <a href="#ijms-25-10876-f004" class="usa-link">Figure 4</a>E). Additionally, we analyzed some samples with <em>TP53</em> missense mutations (with a moderate impact) (chr17:g.7675085C&gt;T, p.Cys176Tyr; chr17:g.7673824C&gt;G, p.Gly266Arg; chr17:g.7676040C&gt;G, p.Arg110Pro; chr17:g.7673776G&gt;A, p.Arg282Trp), for which we observed TP53 accumulation and a strong signal on a membrane (<a href="#ijms-25-10876-f004" class="usa-link">Figure 4</a>E). Interestingly, for <em>CHEK1</em> with a STOP-gain variant (chr11:g.125625996G&gt;A, p.Trp79Ter; <a href="#ijms-25-10876-f004" class="usa-link">Figure 4</a>G), a higher percentage of altered reads resulted in increased CHEK1 expression.</p>
<figure class="fig xbox font-sm" id="ijms-25-10876-f004"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11507582_ijms-25-10876-g004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa32/11507582/5474eaeac950/ijms-25-10876-g004.jpg" loading="lazy" height="632" width="770" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-25-10876-f004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Selected genetic variants and their impact on the expression of corresponding proteins. (<strong>A</strong>) <em>NBN</em> chr8:g.89971217_89971221del (p.Lys219AsnfsTer16): 20% of reads with this sequence alteration (altered reads) in the B79 BOT sample. (<strong>C</strong>) <em>CHEK2</em> chr22:g.28695869del (p.Thr367MetfsTer15): 72% of altered reads in the 410 hgOvCa sample. (<strong>E</strong>) <em>TP53</em> missense variants: 206: chr17:g.7675085C&gt;T (p.Cys176Tyr), 437: chr17:g.7673824C&gt;G (p.Gly266Arg), 485: chr17:g.7676040C&gt;G (p.Arg110Pro), 253: chr17:g.7673776G&gt;A (p.Arg282Trp), 278: chr17:g.7673776G&gt;A (p.Arg282Trp); TP53 non-SNPs with a HIGH impact: 162: chr17:g.7674900dup (p.Thr211AsnfsTer5), 289: chr17:g.7670686del (p.Arg342GlufsTer3), 328: chr17:g.7674241del (p.Cys242AlafsTer5), 394: chr17:g.7676078del (p.Pro98LeufsTer25), 366: chr17:g.7676041_7676042insTTTC (p.Arg110GlufsTer40). Altered reads: 206—64%; 437—72%; 485—71%; 253—84%; 278—63%; 162—67%; 289—52%; 328—43%; 394—40%; 366–50%. (<strong>G</strong>) <em>CHEK1</em> chr11:g.125625996G&gt;A (p.Trp79Ter) in all three tumors. Altered reads: 303—18%; 160—69%; B68—49%. (<strong>B</strong>) Actin as a loading control, detected with a rabbit polyclonal anti-actin Ab, and (<strong>D</strong>,<strong>F</strong>,<strong>H</strong>) vinculin as a loading control, detected with a rabbit polyclonal anti-vinculin Ab. M—protein marker; vinc.—vinculin; ctrl—normal ovary; hg—hgOvCa; lg—lgOvCa; Ab—antibody.</p></figcaption></figure><figure class="fig xbox font-sm" id="ijms-25-10876-f005"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11507582_ijms-25-10876-g005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa32/11507582/4d77304e9e5d/ijms-25-10876-g005.jpg" loading="lazy" height="818" width="737" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-25-10876-f005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Frequent genetic variants in the <em>FANCI</em> and <em>FANCD2</em> genes and their impact on the expression of corresponding proteins. (<strong>A</strong>) the <em>FANCI</em> chr15:g.89285210C&gt;T (p.Leu605Phe) variant; altered reads: B77—51%, 558—92%, 549—85%, 366—45%, 305—86%, 278—33%, 253—32%. No relationship between the percentage of altered reads and the protein level was observed. (<strong>B</strong>) FANCD2 expression for the same cases as in (<strong>A</strong>). (<strong>E</strong>) Expression of FANCD2 in the cases with the most frequently occurring <em>FANCD2</em> variant: chr3:g.10073349G&gt;T (p.Gly901Val). No relationship between the presence of this variant, the percentage of altered reads (<strong>H</strong>), and the protein level was observed. (<strong>G</strong>) A table showing the occurrence of <em>FANCD2</em> and <em>BRCA1/2</em> variants in samples with the <em>FANCI</em> chr15:g.89285210C&gt;T variant. (<strong>C</strong>,<strong>D</strong>,<strong>F</strong>) Loading controls. A rabbit polyclonal anti-actin or anti-vinculin primary antibody was used to detect actin (<strong>C</strong>,<strong>F</strong>) and vinculin (<strong>D</strong>), respectively. Ctrl—normal ovary; hg—hgOvCa; lg—lgOvCa.</p></figcaption></figure><p>Moreover, we found out that the expression of FANCI and its protein partner, FANCD2, was mutually correlated and likely dependent on the presence of genetic variants in the <em>BRCA1/2</em> genes. Tumor cases with the <em>FANCI</em> chr15:g.89285210C&gt;T (p.Leu605Phe) variant did not show any specific pattern of FANCI expression (<a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>A). However, the same samples had a similar pattern of FANCD2 expression (<a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>B), regardless of whether they harbored variants in <em>FANCD2</em> (<a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>G). Yet, the occurrence of FANCD2 expression seemed to depend on the presence of <em>BRCA1/2</em> genetic alterations (<a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>G). In the absence of sequence variants in these two genes, no signal for altered FANCI, and concomitantly for FANCD2, was observed on membranes (compare <a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>G and <a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>A,B). Additionally, we tested whether the most frequent variant in <em>FANCD2</em> (chr3:g.10073349G&gt;T; p.Gly901Val) affected the FANCD2 expression, which revealed no relationship (<a href="#ijms-25-10876-f005" class="usa-link">Figure 5</a>E,H).</p></section></section><section id="sec3-ijms-25-10876"><h2 class="pmc_sec_title">3. Discussion</h2>
<p>The aim of this study was the analysis of genetic variants in crucial tumor suppressors and oncogenes in ovarian tumors of different aggressiveness. We not only evaluated the polymorphic status of these genes in large, thoroughly characterized cohorts of OvCa and BOTS, but we also found predictive and/or prognostic markers for both tumor groups and analyzed the functional role of selected polymorphisms regarding their influence on the expression of the corresponding proteins.</p>
<p>Unexpectedly, our NGS results, obtained for the 44-gene panel, showed that the number of SNPs with a high or moderate or only moderate impact on the structure and/or function of the corresponding proteins was higher in BOT compared to BOT.V600E, lgOvCa, or hgOvCa. Conversely, when analyzing only hot spots in selected genes, the frequency of SNP variants with these impacts was significantly lower in BOT than in both OvCa groups. This apparent discrepancy may be explained by the fact that the two panels investigated in this study contained different sets of genes. As proven in the present study, the list of genes from the 44-gene panel more frequently mutated in BOT compared to the other tumor groups (<em>FANCB</em>, <em>SEM1</em>, <em>FANCA</em>, <em>BRCA2</em>, <em>CHEK2</em>, <em>MUTYH</em>, <em>RAD50</em>) was much longer than analogically altered genes in the hot-spot panel (<em>KRAS</em> only). Additionally, the hot-spot panel was designed to investigate well-known genetic alterations. By contrast, in the 44-gene panel, an approximately 10 times bigger region of the genome was covered, enabling the detection of rare genetic variants, usually omitted in, e.g., diagnostic approaches. Nevertheless, when only polymorphisms with a high impact on a protein function and/or structure were considered, the number of genetic variants identified in both panels was the highest in hgOvCa, thus supporting the general knowledge about ovarian carcinomas [<a href="#B20-ijms-25-10876" class="usa-link" aria-describedby="B20-ijms-25-10876">20</a>,<a href="#B21-ijms-25-10876" class="usa-link" aria-describedby="B21-ijms-25-10876">21</a>].</p>
<p>The mutational status of <em>TP53</em> can be considered one of the best markers differentiating hgOvCa (frequent mutations in <em>TP53</em>) from BOTS (no or very rare mutations) [<a href="#B11-ijms-25-10876" class="usa-link" aria-describedby="B11-ijms-25-10876">11</a>,<a href="#B22-ijms-25-10876" class="usa-link" aria-describedby="B22-ijms-25-10876">22</a>,<a href="#B23-ijms-25-10876" class="usa-link" aria-describedby="B23-ijms-25-10876">23</a>] and lgOvCa (relatively rare mutations) [<a href="#B24-ijms-25-10876" class="usa-link" aria-describedby="B24-ijms-25-10876">24</a>]. In line with these reports, TP53 was one of the most frequently altered genes in the present study, mainly in hgOvCa. By contrast, no variants in <em>TP53</em> were found in our lgOvCa cases, besides two poorly covered high-impact SNPs in one lgOvCa specimen. Interestingly, these SNPs were detected only in the hot-spot panel, making use of a novel NGS hybridization capture technology (known as Primer Extension Target Enrichment, KAPA HyperPETE, Roche), offering much better sequencing coverage uniformity than the older hybridization-based capture approach (KAPA HyperCap, Roche), utilized in the 44-gene panel [<a href="#B25-ijms-25-10876" class="usa-link" aria-describedby="B25-ijms-25-10876">25</a>]. As for BOTS, the only two missense variants in <em>TP53</em> found in this study were observed in two BOT samples of a mucinous subtype. This outcome aligns with the current state of the knowledge too, given that Kang et al. reported TP53 mutations in 19.4% of mucinous BOTS, which was associated with a higher risk of recurrence [<a href="#B26-ijms-25-10876" class="usa-link" aria-describedby="B26-ijms-25-10876">26</a>]. Consistently, one of our two <em>TP53</em> mutation-bearing BOT patients had progression to OvCa. Noteworthy, herein, we also managed to confirm our NGS results for <em>TP53</em> on the protein level by observing both the lack of TP53 in samples with high-impact non-SNP variants and TP53 accumulation in tumors harboring <em>TP53</em> missense SNPs. These results are in line with our previous immunohistochemical evaluation of TP53 expression [<a href="#B27-ijms-25-10876" class="usa-link" aria-describedby="B27-ijms-25-10876">27</a>].</p>
<p>According to the literature, alongside genetic aberrations in <em>TP53</em>, mutations in <em>BRCA1/2</em> are also frequent in hgOvCa [<a href="#B24-ijms-25-10876" class="usa-link" aria-describedby="B24-ijms-25-10876">24</a>,<a href="#B28-ijms-25-10876" class="usa-link" aria-describedby="B28-ijms-25-10876">28</a>] and are rare in BOTS and lgOvCa [<a href="#B3-ijms-25-10876" class="usa-link" aria-describedby="B3-ijms-25-10876">3</a>,<a href="#B9-ijms-25-10876" class="usa-link" aria-describedby="B9-ijms-25-10876">9</a>,<a href="#B10-ijms-25-10876" class="usa-link" aria-describedby="B10-ijms-25-10876">10</a>,<a href="#B24-ijms-25-10876" class="usa-link" aria-describedby="B24-ijms-25-10876">24</a>]. Our results obtained with the 44-gene panel do not seem fully consistent with the literature, as we found variants in <em>BRCA1/2</em> genes in many non-high-grade ovarian tumors. However, it needs to be emphasized that, except for one SNP in a single BOT, these were only moderate-impact variants. These variants accounted for the significantly higher number of genetic alterations found in <em>BRCA1/BRCA2</em> in BOT compared to hgOvCa. Yet, when only high-impact variants were considered, <em>BRCA1</em> (but not <em>BRCA2</em>) was, as expected, more frequently altered in hgOvCa in comparison with all the remaining tumor groups. By contrast, in the hot-spot panel, which concentrated on well-established variants only and omitted most of the poorly investigated genetic alterations, no <em>BRCA1</em> polymorphisms with a high/moderate impact were found in BOT or lgOvCa, and only a single moderate-impact variant was present in one BOT.V600E sample. As a consequence, when only commonly analyzed hot spots in the <em>BRCA1</em> gene were taken into account, our statistical workflow corroborated the generally acknowledged predominance of sequence variants in this gene in hgOvCa compared to BOT. Still, according to a recent NGS study, carried out on big cohorts (containing 1333 OvCa and 152 BOTS patients), the prevalences of <em>BRCA1/2</em> mutations are similar in hgOvCa and BOTS (30.9% and 28.9%, respectively) [<a href="#B29-ijms-25-10876" class="usa-link" aria-describedby="B29-ijms-25-10876">29</a>]. Thus, this paper seems to corroborate our finding, made with the 44-gene panel, that lots of genetic alterations in <em>BRCA1</em> are detectable in BOTS if high-throughput sequencing techniques (not limited to known hot spots only) are applied. As for <em>BRCA2</em>, similarly to <em>BRCA1</em>, the moderate-impact variants of this gene prevailed in BOT compared to hgOvCa. Conversely, we revealed no differences in the frequencies of high-impact <em>BRCA2</em> polymorphisms between the investigated groups of ovarian tumors. Nevertheless, <em>BRCA2</em> emerged in this study as a promising, favorable predictive and prognostic marker in hgOvCa. The presence of sequence variants in <em>BRCA2</em> improved the patient OS, CR, and PS, especially in tumors without TP53 accumulation. Although this outcome may seem odd, given the tumor suppressor capabilities of this gene, a similar phenomenon was earlier observed in small-cell lung cancer [<a href="#B30-ijms-25-10876" class="usa-link" aria-describedby="B30-ijms-25-10876">30</a>], where the authors of the cited research reported a link between the occurrence of <em>BRCA2</em> mutations and the higher sensitivity of tumors to chemotherapy. In line with these findings, data obtained in vitro also provided strong evidence for the better response of BRCA-deficient tumors to platinum drugs, which was further confirmed by ex vivo studies, where <em>BRCA</em> mutation carriers exhibited better survival and longer disease-free intervals upon treatment with platinum drugs [<a href="#B31-ijms-25-10876" class="usa-link" aria-describedby="B31-ijms-25-10876">31</a>]. As BRCA1/BRCA2 proteins are responsible for the repair of double-strand DNA breaks (DSBs), the presence of pathogenic variants in <em>BRCA2</em> leads to the impaired activity of its protein product and thus increases the risk of a DSB in a tumor cell. If such a cell expresses functional TP53 (no TP53 accumulation is observed), apoptosis is induced [<a href="#B32-ijms-25-10876" class="usa-link" aria-describedby="B32-ijms-25-10876">32</a>], thus ameliorating the outcome of platinum-based treatment, as shown herein.</p>
<p>As for genetic alterations characteristic of less aggressive ovarian tumors, the genes with the highest number of polymorphisms in BOTS and lgOvCa compared to hgOvCa were <em>KRAS</em>, <em>BRAF</em>, and <em>NRAS</em>, which is in line with the scientific literature [<a href="#B13-ijms-25-10876" class="usa-link" aria-describedby="B13-ijms-25-10876">13</a>,<a href="#B33-ijms-25-10876" class="usa-link" aria-describedby="B33-ijms-25-10876">33</a>,<a href="#B34-ijms-25-10876" class="usa-link" aria-describedby="B34-ijms-25-10876">34</a>,<a href="#B35-ijms-25-10876" class="usa-link" aria-describedby="B35-ijms-25-10876">35</a>,<a href="#B36-ijms-25-10876" class="usa-link" aria-describedby="B36-ijms-25-10876">36</a>]. Given that BOTS with the <em>BRAF</em> V600E variant occurred in much younger patients than those lacking this mutation [<a href="#B18-ijms-25-10876" class="usa-link" aria-describedby="B18-ijms-25-10876">18</a>], here, both these groups of tumors were analyzed separately. Interestingly, <em>KRAS</em> was more frequently mutated in BOT and lgOvCa than in either BOT.V600E or hgOvCa, while the frequencies of <em>KRAS</em> variants in lgOvCa and BOT were comparable. This confirms the molecular resemblance between these two tumor groups. Simultaneously, such an outcome demonstrates that in BOTS without the <em>BRAF</em> V600E variant (being the most frequent polymorphism in this gene, found in this study in about 72% of <em>BRAF</em>-deficient tumors), KRAS-activating mutations are present. The KRAS-dependent cancer-promoting mechanism hinges mainly on mutations in the Gly12(G12)-coding region of the gene [<a href="#B37-ijms-25-10876" class="usa-link" aria-describedby="B37-ijms-25-10876">37</a>,<a href="#B38-ijms-25-10876" class="usa-link" aria-describedby="B38-ijms-25-10876">38</a>], which, in our research, predominated in BOT and lgOvCa alike. By contrast, none of the <em>KRAS</em> polymorphisms, which we found in a few hgOvCa tumors, affected Gly12. Furthermore, it is worth mentioning that all three of our BOT cases with <em>BRAF</em> variants other than V600E (i.e., K601E, G466R, and G466V) simultaneously harbored <em>KRAS</em> G12 variants. This suggests that out of all the <em>BRAF</em> polymorphisms, only <em>BRAF</em> V600E exerts a sufficiently strong cancer-promoting effect to act independently of <em>KRAS</em> mutations [<a href="#B39-ijms-25-10876" class="usa-link" aria-describedby="B39-ijms-25-10876">39</a>]. As for <em>NRAS</em> variants, their prevalence differentiated lgOvCa from all the other tumor groups investigated in our study. This outcome supports the finding of others that mutations in <em>NRAS</em> are found in serous lgOvCa but not, or rarely, in serous BOTS [<a href="#B40-ijms-25-10876" class="usa-link" aria-describedby="B40-ijms-25-10876">40</a>]. Similarly to activating mutations in <em>KRAS</em>, their counterparts in <em>NRAS</em> also speed up tumor progression. Moreover, such variants are found in recurrent serous lgOvCa too [<a href="#B41-ijms-25-10876" class="usa-link" aria-describedby="B41-ijms-25-10876">41</a>,<a href="#B42-ijms-25-10876" class="usa-link" aria-describedby="B42-ijms-25-10876">42</a>]. In this context, it is worth mentioning that one of our serous BOT samples with microinvasions harbored the NRAS-activating variant (p.Gln61Arg) [<a href="#B43-ijms-25-10876" class="usa-link" aria-describedby="B43-ijms-25-10876">43</a>], which occurred most frequently in our lgOvCa group as well. The presence of such a mutation in a BOT sample not only constitutes further confirmation of the molecular similarity between BOT and lgOvCa [<a href="#B5-ijms-25-10876" class="usa-link" aria-describedby="B5-ijms-25-10876">5</a>,<a href="#B44-ijms-25-10876" class="usa-link" aria-describedby="B44-ijms-25-10876">44</a>] but also implies that this BOT tumor might have transformed and recurred as lgOvCa if it had not been completely excised. According to the literature, in advanced ovarian carcinomas, <em>NRAS</em> mutations are rare [<a href="#B45-ijms-25-10876" class="usa-link" aria-describedby="B45-ijms-25-10876">45</a>]. Consistently, we did not identify such genetic alterations in our hgOvCa series. Of note, mutations in the <em>KRAS</em>, <em>NRAS</em>, and <em>BRAF</em> genes have also been reported in other human malignancies, e.g., colorectal and endometrial cancers [<a href="#B46-ijms-25-10876" class="usa-link" aria-describedby="B46-ijms-25-10876">46</a>,<a href="#B47-ijms-25-10876" class="usa-link" aria-describedby="B47-ijms-25-10876">47</a>,<a href="#B48-ijms-25-10876" class="usa-link" aria-describedby="B48-ijms-25-10876">48</a>,<a href="#B49-ijms-25-10876" class="usa-link" aria-describedby="B49-ijms-25-10876">49</a>].</p>
<p>Genes encoding proteins involved in ubiquitination were also more frequently altered in BOT and differentiated these tumors from OvCa (but not from BOT.V600E). One of these genes, <em>SEM1</em>, which codes for a 26S proteasome subunit [<a href="#B17-ijms-25-10876" class="usa-link" aria-describedby="B17-ijms-25-10876">17</a>], was very often altered in all the tumor groups. Although the most frequent variant, found in all the tumor groups, p.Gln59Pro is widespread in the human population (maximum allele frequency (AF<sub>max</sub>) of 0.88); still, the overall number of <em>SEM1</em> variants was significantly higher in BOT than in either lgOvCa or hgOvCa. Nowadays, no scientific reports on the role of this polymorphism in tumors are available. For the second gene, <em>FANCB</em>, which encodes a DNA repair-involved protein required for FANCD2 ubiquitination [<a href="#B17-ijms-25-10876" class="usa-link" aria-describedby="B17-ijms-25-10876">17</a>], literature data concerning OvCa are scarce, while its function in BOTS has not been studied so far. <em>FANCB</em> missense mutations were shown to cause the instability of the catalytic module and Fanconi Anemia (FA) core complex dysfunction. By contrast, SNPs in the <em>FANCB</em> 3′UTR did not affect the expression or function of the protein [<a href="#B50-ijms-25-10876" class="usa-link" aria-describedby="B50-ijms-25-10876">50</a>]. Given that all the <em>FANCB</em> polymorphisms found in our research were located in the coding sequence of the gene, their occurrence may likely impair the FANCB function, as proven in the study cited above. Interestingly, according to the current state of the knowledge, the <em>FANCB</em> role in cancer seems discrepant. On the one hand, no mutations in this gene in hereditary breast/ovarian cancers were found [<a href="#B51-ijms-25-10876" class="usa-link" aria-describedby="B51-ijms-25-10876">51</a>] and no associations between <em>FANCB</em> and the development of <em>BRCA1/2</em>-negative familial cancers were demonstrated [<a href="#B50-ijms-25-10876" class="usa-link" aria-describedby="B50-ijms-25-10876">50</a>]. On the other hand, Matta et al. [<a href="#B50-ijms-25-10876" class="usa-link" aria-describedby="B50-ijms-25-10876">50</a>] unraveled the relationship between the expression of <em>FANCB</em> and breast cancer in older patients with decreased DNA repair capacities. In this context, our results appear to shed new light on the clinical importance of <em>FANCB</em>, showing that this gene may play more important roles in BOTS than in OvCa.</p>
<p>Our regression analysis revealed genetic variants in <em>PARP1</em> as a marker of a poor prognosis in BOTS. This gene encodes a protein activated by DNA damage, regulating the function of many tumor suppressors, including TP53 [<a href="#B52-ijms-25-10876" class="usa-link" aria-describedby="B52-ijms-25-10876">52</a>]. In the literature, the data on the <em>PARP1</em> role in BOTS are limited; however, its meaning in OvCa has been profoundly investigated [<a href="#B53-ijms-25-10876" class="usa-link" aria-describedby="B53-ijms-25-10876">53</a>,<a href="#B54-ijms-25-10876" class="usa-link" aria-describedby="B54-ijms-25-10876">54</a>]. Consequently, PARP inhibitors have been approved for the maintenance treatment of recurrent platinum-sensitive <em>BRCA1</em>/<em>2</em>-deficient OvCa. Yet, newer data demonstrated therapeutic benefits in tumors beyond those with <em>BRCA1/2</em> mutations [<a href="#B55-ijms-25-10876" class="usa-link" aria-describedby="B55-ijms-25-10876">55</a>]. Remarkably, the most frequent <em>PAPR1</em> polymorphism in all the groups of tumors analyzed herein, p.Val762Ala, was different from that causing resistance to olaparib, one of the PARP inhibitors [<a href="#B56-ijms-25-10876" class="usa-link" aria-describedby="B56-ijms-25-10876">56</a>]. Despite its predominance in the human population (AF<sub>max</sub> around 45%), the p.Val762Ala variant was previously shown to be associated with several types of cancer, including gallbladder cancer [<a href="#B57-ijms-25-10876" class="usa-link" aria-describedby="B57-ijms-25-10876">57</a>,<a href="#B58-ijms-25-10876" class="usa-link" aria-describedby="B58-ijms-25-10876">58</a>]. The same polymorphism also increased the risk of breast cancer among the Saudi and Asian populations, simultaneously decreasing this risk among Caucasians [<a href="#B59-ijms-25-10876" class="usa-link" aria-describedby="B59-ijms-25-10876">59</a>]. Interestingly, though other scientists reported that <em>PARP1</em> expression in serous OvCa is higher than in BOTS [<a href="#B60-ijms-25-10876" class="usa-link" aria-describedby="B60-ijms-25-10876">60</a>], in our hgOvCa series, this gene was neither more frequently altered nor identified as a potential biomarker.</p>
<p>Polymorphisms in two other genes encoding proteins involved in the FA pathway, FANCF and FANCI, were identified herein as promising outcome predictors in hgOvCa. Noteworthy, variants in <em>FANCI</em> exhibited significantly better discriminative capabilities than those in <em>FANCF</em>, as assessed based on the AUC values. The FANCI protein forms a heterodimer with FANCD2, which is subsequently monoubiquitinated by the FA core complex. Such a heterodimer localizes to the damaged chromatin and promotes interstrand crosslink repair [<a href="#B50-ijms-25-10876" class="usa-link" aria-describedby="B50-ijms-25-10876">50</a>]. In our analyses, the presence of variants in the <em>FANCI</em> gene increased the risk of recurrence in the TP-treated patients with tumors lacking the TP53 accumulation. When the literature data are considered, the role of <em>FANCI</em> seems ambiguous, as this gene has been reported to play both oncogenic and tumor suppressor roles [<a href="#B61-ijms-25-10876" class="usa-link" aria-describedby="B61-ijms-25-10876">61</a>,<a href="#B62-ijms-25-10876" class="usa-link" aria-describedby="B62-ijms-25-10876">62</a>]. Moreover, <em>FANCI</em> was recently proposed as a new OvCa-predisposing gene in carriers of the <em>FANCI</em> p.Leu605Phe variant [<a href="#B63-ijms-25-10876" class="usa-link" aria-describedby="B63-ijms-25-10876">63</a>], the frequency of which turned out to be significantly higher in OvCa-prone families with normal <em>BRCA1/2</em> genes [<a href="#B64-ijms-25-10876" class="usa-link" aria-describedby="B64-ijms-25-10876">64</a>]. In vitro studies revealed that the Leu605Phe isoform of FANCI was expressed at a reduced level and conferred sensitivity on HeLa and OvCa cells to cisplatin but not to a PARP inhibitor [<a href="#B64-ijms-25-10876" class="usa-link" aria-describedby="B64-ijms-25-10876">64</a>]. Consistently, our WB analyses revealed that tumors with the <em>FANCI</em> p.Leu605Phe variant and normal <em>BRCA1/2</em> genes did not express mutated FANCI, in contrast to <em>BRCA1/2</em>-deficient tumors, where FANCI expression was detected. Additionally, the same WB analysis unraveled the correlation between the expression of the FANCI and FANCD2 proteins. All these results clearly suggest that the role of <em>FANCI</em> depends on the molecular background in the cell controlled by crucial tumor suppressors, such as BRCA1/2 and TP53.</p>
<p>Our last result worth discussing deals with <em>CHEK1</em> for the nonsense variant in which (chr11:g.125625996G&gt;A, p.Trp79Ter) we observed the unexpectedly high expression of the CHEK1 protein. Interestingly, both molecular phenomena seemed to be positively correlated (the higher the percentage of the altered allele, the stronger the signal for CHEK1 on a membrane). The SNP in question is located in the first exon/5’UTR region of <em>CHEK1</em>. If the longest isoform of CHEK1 (<a href="https://www.ncbi.nlm.nih.gov/protein/XP_011540862.1" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">XP_011540862.1</a>) is considered, the discussed polymorphism leads to the formation of a premature stop codon. In such a case, the utilization of an alternative start codon located downstream from the newly formed stop codon may not only restore the CHEK1 expression as a shorter isoform but concomitantly affect its levels in the cell. Consistently, according to the literature, short CHEK1 isoforms may occur due to alternative splicing or protein cleavage [<a href="#B65-ijms-25-10876" class="usa-link" aria-describedby="B65-ijms-25-10876">65</a>]. The role of <em>CHEK1</em> in tumorigenesis is ambiguous. Initially, CHEK1 was thought to be a tumor suppressor because of the role it plays in the DNA damage response and cell cycle checkpoint response [<a href="#B66-ijms-25-10876" class="usa-link" aria-describedby="B66-ijms-25-10876">66</a>]. However, no evidence of homozygous loss of function <em>CHEK1</em> mutants in human cancers was found. Moreover, the <em>CHEK1</em> gene was overexpressed in several solid tumors, and its expression was correlated with the tumor grade and disease recurrence [<a href="#B67-ijms-25-10876" class="usa-link" aria-describedby="B67-ijms-25-10876">67</a>]. In step with these findings, the complete loss of <em>CHEK1</em> suppresses chemically induced carcinogenesis, whereas tumor cells with increased levels of <em>CHEK1</em> may acquire survival advantages due to the ability to resist chemotherapy-induced DNA damage. As a result, reduced survival rates of patients with high <em>CHEK1</em> expression were reported in bladder, brain, lung, ovary, and breast cancers [<a href="#B67-ijms-25-10876" class="usa-link" aria-describedby="B67-ijms-25-10876">67</a>]. Although our results do not elucidate whether CHEK1 acts more like an oncogene or suppressor in ovarian tumors, further investigation of its variants appears interesting in the context of potential targeted therapies with Prexasertib, a selective CHEK1 inhibitor. Its application, either as a single agent or in combination with PARP inhibitors, stimulated tumor regression and prolonged hgOvCa patient survival [<a href="#B68-ijms-25-10876" class="usa-link" aria-describedby="B68-ijms-25-10876">68</a>]. This combination of inhibitors could be of potential use in BOTS, since <em>PARP1</em> polymorphisms were identified herein as a negative prognostic marker in these tumors, while some BOTS also harbored the above-described <em>CHEK1</em> p.Trp79Ter variant.</p>
<p>Finally, as with every study, this one also has some limitations that ought to be mentioned here. Although we managed to identify numerous genetic variants, due to financial and time-related constraints, the functional validation was only performed for a small subset of these polymorphisms. Thus, the clinical significance of many identified variants, listed in the <a href="#app1-ijms-25-10876" class="usa-link">Supplement-variants.xlsx file</a>, remains unclear and should be addressed in future research. Furthermore, it needs to be emphasized that in our bioinformatic workflow, all sequence variants less frequent than 10% were filtered out. This approach was utilized to reduce the rate of false-positive hits, yet, hypothetically, some rare, clinically important polymorphisms may have been excluded from the analysis too. The next limitation worth bringing up results from the fact that we analyzed bulk tumor samples, which are just a part of the entire tumor microenvironment, the complexity and heterogeneity of which might not have been fully captured due to the constraints of the experimental setup applied in this study. Also, in terms of the tumor complexity and heterogeneity, we are aware that the loading controls in our Western blot experiments sometimes differed between lysates from distinct OvCa samples analyzed on the same gel. This inconsistency was not caused by any laboratory error or imprecision but, rather, is related to the vast biodiversity of ovarian tumors, especially high-grade OvCa, which results from the genomic and proteomic instability of such malignancies [<a href="#B69-ijms-25-10876" class="usa-link" aria-describedby="B69-ijms-25-10876">69</a>]. In the present study, to diminish the risk of drawing false conclusions, the concentration of all the protein lysates was not only assessed by Ponceau S red staining but was also precisely measured and normalized with the BCA method and a standard curve for bovine serum albumin (BSA). In the end, the present research was performed on a retrospective (not prospective) cohort of patients, collected for 20 years, meticulously followed up, and carefully checked for the compatibility of all the clinicopathological parameters. This approach, though widely used, could introduce some hardly definable biases and limit the ability to control for potential confounding factors.</p></section><section id="sec4-ijms-25-10876"><h2 class="pmc_sec_title">4. Materials and Methods</h2>
<section id="sec4dot1-ijms-25-10876"><h3 class="pmc_sec_title">4.1. Patients and Clinicopathological Parameters</h3>
<p>In this study, a retrospective set of 225 non-consecutive ovarian tumor samples was used, including 76 BOTS (61 of the serous type and 15 of other histological types), 10 lgOvCa (9 of the serous type and 1 of another type), and 139 hgOvCa (113 of the serous type and 26 of other types). All the samples were collected from an ethnically uniform cohort of patients of central European origin, hospitalized at the Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, in the years 1995–2015. The corresponding medical records were critically reviewed by at least two physicians. Out of 76 BOTS, 21 were collected as snap-frozen samples, whereas the remaining 55 specimens were available in the form of formalin-fixed, paraffin-embedded (FFPE) blocks only. By contrast, all our OvCa samples were snap-frozen. The detailed clinicopathological characteristics for the BOTS and OvCa are presented in <a href="#app1-ijms-25-10876" class="usa-link">Supplementary Tables S1 and S2</a>, respectively. For two lgOvCa, the information on the applied chemotherapy was missing, which was one of the grouping variables in our study. Therefore, these samples were excluded from <a href="#app1-ijms-25-10876" class="usa-link">Table S2</a>. As for the evaluation of the clinical endpoints, all surviving patients had at least a 3-year follow-up. The specimens were carefully selected to meet the following criteria: an adequate staging procedure (stages were assessed for all cancers and primary BOTS) according to the recommendations by the International Federation of Gynecologists and Obstetricians (FIGO) [<a href="#B70-ijms-25-10876" class="usa-link" aria-describedby="B70-ijms-25-10876">70</a>], tumor tissue from the first laparotomy available, availability of clinical data including patient age and follow-up, as well as tumor histological type and grade and residual tumor size. Noteworthy, all BOT patients were characterized by no residual disease. All tumors were uniformly histopathologically reviewed and classified according to the new WHO criteria [<a href="#B5-ijms-25-10876" class="usa-link" aria-describedby="B5-ijms-25-10876">5</a>,<a href="#B71-ijms-25-10876" class="usa-link" aria-describedby="B71-ijms-25-10876">71</a>]. Additionally, a complete evaluation of the genetic variants in the <em>TP53</em> gene (for all tumors) and the TP53 protein status (for cancers only) was performed by either next-generation sequencing or with the PAb1801 mouse monoclonal antibody (1:500, Sigma-Genosys, Cambridge, UK), as described previously [<a href="#B27-ijms-25-10876" class="usa-link" aria-describedby="B27-ijms-25-10876">27</a>]. Most BOT patients (<em>n</em> = 60) did not undergo any chemical treatment. The remaining individuals suffering from BOTS (<em>n</em> = 16) received chemotherapy, administered either pre- or postoperatively. All carcinomas were excised from previously untreated patients. A total of 35 OvCa patients were treated postoperatively with platinum/cyclophosphamide (PC), while 112 of them underwent the taxane/platinum (TP) treatment after a surgical intervention. In BOTS, the relapse-free survival time (RFS) and the presence of microinvasions or implants within the tumor masses were used as dependent variables determining the disease outcome. The chemotherapy administration status was used as an independent logical variable in the multivariable statistical analyses. Other covariates taken into account in the multivariable statistical inference in BOTS were a logical variable determining whether the tumor was primary, the tumor histological type, and the patient age (continuous variable). In addition, BOTS were analyzed in the entire cohort of patients, and in subgroups comprising either BOT.V600E or BOT specimens only, since the presence of the <em>BRAF</em> V600E mutation was previously found to be significantly correlated with the lower age of patients diagnosed with BOTS [<a href="#B18-ijms-25-10876" class="usa-link" aria-describedby="B18-ijms-25-10876">18</a>]. For cancers, the overall survival (OS) and disease-free survival (DFS) of patients were used as dependent prognostic variables, while the platinum sensitivity (PS) and complete remission (CR) served as dependent factor variables predictive of the tumors’ response to treatment. CR was defined as the disappearance of all clinical and biochemical symptoms of ovarian cancer assessed after completion of the first-line chemotherapy and confirmed four weeks later [<a href="#B72-ijms-25-10876" class="usa-link" aria-describedby="B72-ijms-25-10876">72</a>]. DFS was assessed only for the patients who achieved CR. As for the independent variables used in the statistical analyses in cancers, the histological type and clinical stage of the tumors along with the residual tumor size were taken into account as factor variables in the multivariable statistical models. Noteworthy, due to the small size of the lgOvCa subgroup, only hgOvCa samples were subjected to the regression analyses performed in the present study. The hgOvCa were investigated in either the entire set of samples or in subgroups depending on the chemotherapy regimen used (PC/TP) and/or the TP53 accumulation status. Notably, two of the above-mentioned lgOvCa samples excluded from <a href="#app1-ijms-25-10876" class="usa-link">Table S2</a> were taken into account in the entire bioinformatic workflow presented herein, except for the Cox and logistic regression analyses, which required detailed clinicopathological information.</p></section><section id="sec4dot2-ijms-25-10876"><h3 class="pmc_sec_title">4.2. DNA Isolation and Quality Assessment</h3>
<p>Genomic DNA (gDNA) from snap-frozen sections was isolated using the QIAmp DNA Mini Kit (Qiagen; Hilden, Germany), whereas gDNA from FFPE blocks was extracted on the MagCore Nucleic Acid Extractor machine using the MagCore Genomic DNA FFPE One-Step Kit (RBC Biosciences, Xinbei City, Taiwan). gDNA concentrations were measured on the Qubit 4 Fluorometer (Thermo Fisher Scientific (Thermo), Waltham, MA, USA) using the Qubit dsDNA HS Assay Kit (Thermo). Before the construction of the NGS libraries, the gDNA quality was assessed using our in-house-developed method based on the comparison of the real-time quantitative PCR (qPCR) efficiency for two amplicons of different lengths, described in the paper by Woroniecka et al. [<a href="#B73-ijms-25-10876" class="usa-link" aria-describedby="B73-ijms-25-10876">73</a>].</p></section><section id="sec4dot3-ijms-25-10876"><h3 class="pmc_sec_title">4.3. Construction of Total gDNA Libraries; 44-Gene Panel Enrichment and Verification; NGS Sequencing</h3>
<p>For the libraries’ construction, 120–500 ng of gDNA was used. Libraries were created using the KAPA Hyperplus Kit (Roche, Basel, Switzerland) according to the protocol provided by the producer. The verification of the libraries’ size was made on 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Total gDNA libraries were then enriched in exonic sequences of the following 44 genes: <em>ATM</em>, <em>ATR</em>, <em>ATRX</em>, <em>BAP1</em>, <em>BARD1</em>, <em>BCL2L1</em>, <em>BLM</em>, <em>BRCA1</em>, <em>BRCA2</em>, <em>BRIP1</em>, <em>CCNE1</em>, <em>CEBPA</em>, <em>CHEK1</em>, <em>CHEK2</em>, <em>CRNDE</em>, <em>EMSY</em>, <em>FANCA</em>, <em>FANCB</em>, <em>FANCC</em>, <em>FANCD2</em>, <em>FANCE</em>, <em>FANCF</em>, <em>FANCG</em>, <em>FANCI</em>, <em>FANCL</em>, <em>FANCM</em>, <em>IRX5</em>, <em>MDM2</em>, <em>MRE11</em>, <em>MUTYH</em>, <em>NBN</em>, <em>PALB2</em>, <em>PARP1</em>, <em>PIK3CA</em>, <em>PRKDC</em>, <em>PTEN</em>, <em>RAD50</em>, <em>RAD51B</em>, <em>RAD51C</em>, <em>RAD51D</em>, <em>RAD54L</em>, <em>RPA1</em>, <em>SEM1</em>, and <em>TP53</em>, using the SeqCap EZ Hybridization&amp;Wash Kit with biotinylated hybridization probes (Roche). Out of these genes, 41 were involved in hereditary ovarian carcinoma development (as stated in the description of the Ion AmpliSeq™ Comprehensive Ovarian Cancer Research Panel, Thermo). The remaining three genes, <em>CRNDE</em>, <em>IRX5</em>, and <em>CEBPA</em>, were added by our team to further extend the functionality of this panel. The whole enriched region covered ca 360,000 bp in the genome. The verification of the DNA enrichment was performed by qPCR with four pairs of primers designed by Roche. The list of primers and the results of the enrichment evaluation for each primer pair are presented in <a href="#app1-ijms-25-10876" class="usa-link">Figure S4A</a>–D,F. The NGS libraries were sequenced on the NovaSeq 6000 Platform (Illumina, San Diego, CA, USA) in the paired-end mode (2 × 100 bp for DNA obtained from frozen material or 2 × 75 bp for DNA isolated from FFPE blocks). The resultant BAM files were deposited in the European Nucleotide Archive (ENA) database (data acc. no. PRJEB75542).</p></section><section id="sec4dot4-ijms-25-10876"><h3 class="pmc_sec_title">4.4. Hot-Spot Panel Enrichment and Verification; NGS Sequencing</h3>
<p>For the hot-spot analysis, total gDNA libraries, also employed for the 44-gene panel, were used. The enrichment in 37 genes frequently mutated in sporadic human cancers (<em>AKT1</em>, <em>ALK</em>, <em>APC</em>, <em>ATM</em>, <em>BRAF</em>, <em>BRCA1</em>, <em>CDKN2A</em>, <em>CTNNB1</em>, <em>EGFR</em>, <em>ERBB2</em>, <em>ESR1</em>, <em>FBXW7</em>, <em>FGFR1</em>, <em>FGFR2</em>, <em>FGFR3</em>, <em>GNA11</em>, <em>GNAQ</em>, <em>GNAS</em>, <em>HRAS</em>, <em>IDH1</em>, <em>IDH2</em>, <em>JAK2</em>, <em>KIT</em>, <em>KRAS</em>, <em>NF1</em>, <em>NRAS</em>, <em>NTRK3</em>, <em>PDGFRA</em>, <em>PIK3CA</em>, <em>POLE</em>, <em>PTCH1</em>, <em>PTEN</em>, <em>RET</em>, <em>STK11</em>, <em>TP53</em>, <em>TSC1</em>, <em>TSC2</em>) was performed using the KAPA HyperPETE Hot Spot Panel (Roche). The whole enriched region covered approximately 36,000 bp in the human genome. The verification of the gDNA enrichment was performed using qPCR with one pair of our in-house-designed primers for <em>TP53</em> exon 4. For the enrichment verification results and PCR primer sequences, refer to <a href="#app1-ijms-25-10876" class="usa-link">Figure S4E,F</a>. The NGS libraries were sequenced on the iSeq100 platform (Illumina) in the paired-end mode (2 × 150 bp for DNA obtained from frozen material or 2 × 100 bp for DNA isolated from FFPE blocks). The resultant BAM files were deposited in the ENA database (data acc. no. PRJEB75531).</p></section><section id="sec4dot5-ijms-25-10876"><h3 class="pmc_sec_title">4.5. Bioinformatic Analyses</h3>
<p>The quality of our NGS data (FASTQ files) was assessed with the FASTQC app (v. 0.12.1) and then optimized with Trimmomatic (v. 0.39). Mapping to the reference human genome (hg38) was performed using the HISAT2 aligner (v. 2.2.1). Afterward, the mapping quality was evaluated with the Samtools (v. 1.6), Genome Analysis Toolkit (v. v4.5.0.0), and Qualimap (v. 2.3) apps. Next, our in-house-developed software, SeqDepth_checker (v. 1.0, downloadable from <a href="https://github.com/lukszafron" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/lukszafron</a>, LMS_gh, accessed on 29 May 2024), was utilized to evaluate the mean sequencing read coverage depths for each region enriched in every gene. If the mean coverage depth for a given region was lower than 5, this region was excluded from further analyses to diminish the risk of considering unevenly enriched DNA regions as non-mutated in samples with poor enrichment. The obtained BAM files were subsequently analyzed with bcftools software (v. 1.18) to create VCF files with the AD tag. Next, the variants were subjected to two-step filtering. First, variants less frequent than 10% were filtered out based on the AD tag, using the VAF checker app (version: 1.0), a program available for download at LMS_gh. Then, the vcf-annotate app from the VCFtools package (version: 0.1.16) was employed to filter out variants that did not meet the following criteria: all filters with default values applied, except for MinAB = 2 (a minimum number of alternate bases of 2), Qual = 20 (minimum sequence quality of 20), MinMQ = 20 (minimum mapping quality of 20), and MinDP = 5 (minimum sequence coverage depth of 5). Subsequently, the obtained VCF files were divided with bcftools into two subsets, SNPs and non-SNPs, containing SNP variants vs. all other sequence alterations, i.e., indels (insertions, deletions), mnps (multi-nucleotide polymorphisms), bnd (breakpoints), and others, respectively. Next, the variant identification and effect prediction analysis was carried out using the Ensembl Variant Effect Predictor (VEP) app (v. 109) and the merged Ensembl and RefSeq databases [<a href="#B74-ijms-25-10876" class="usa-link" aria-describedby="B74-ijms-25-10876">74</a>]. The obtained tab-delimited CSV files (VEP output tables) were further analyzed consecutively with two R programs developed by LMS, vep.r (v. 2.2) and vep.comparison.r (v. 2.2), both available for download at LMS_gh. Ensembl VEP divides sequence variants into four categories: high, moderate, low, and modifier, based on their expected impact on the transcript and protein sequences. For details, refer to the Ensembl web page [<a href="#B75-ijms-25-10876" class="usa-link" aria-describedby="B75-ijms-25-10876">75</a>]. The two aforementioned R apps were utilized first to filter out all variants characterized by low or modifier impacts and then to exclude all variants except those that either had a known adverse clinical significance (determined with the CLIN_SIG tag) or negatively affected the protein structure and function (as assessed by either the SIFT or PolyPhen algorithms). The new, previously unidentified sequence variants (with an empty “Existing_variation” field in the VEP output table), variants for which all three “CLIN_SIG”, “SIFT” and “PolyPhen” fields were empty, or those with a maximum allele frequency (MAX_AF) lower than 0.01, were also included in the final report generated by the vep.r app. The analyses were carried out independently for SNP and non-SNP variants. Subsequently, these results were combined with the binarization of sequence alterations for every gene (sequence variants with a high or moderate impact present (1) vs. absent (0)). Afterward, to identify genes with significantly different frequencies of sequence alterations between the investigated groups of ovarian tumors, statistical inference with the chi-squared test or the Fisher’s exact test (depending on the sizes of the analyzed subgroups) was carried out, followed by the data visualization. This final step of the analysis was performed with the vep.comparison.r script. A list of all polymorphic variants for each sample is presented in <a href="#app1-ijms-25-10876" class="usa-link">Supplement-variants.xlsx</a>.</p>
<p>All genes containing variants identified in our bioinformatic analyses were subsequently subjected to detailed statistical inference with the use of univariable and multivariable Cox proportional hazards models (package: survival, v. 3.5.7) to assess the value of these genes as potential novel prognostic biomarkers. All Cox models were also checked with respect to the proportionality of hazards for each variable used. The prediction of the treatment response was carried out by generating univariable and multivariable logistic regression models (packages: stats., v. 4.0.2, and rms, v. 6.0.1). The dependent, independent, and grouping variables (different for BOTS and hgOvCa) are described above in the section entitled Patients and Clinicopathological Parameters. In order to verify the discriminating capabilities of the created Cox and logistic regression models, we performed their cross-validation in new datasets, generated from the original data by bootstrapping (with replacement) and a subsequent comparison of the areas under ROC curves (AUCs) between the original and bootstrapped datasets, using the riskRegression package (v. 2023.12.21) [<a href="#B76-ijms-25-10876" class="usa-link" aria-describedby="B76-ijms-25-10876">76</a>]. The R script written to automate the above-mentioned statistical inference and subsequent visualization of the results (regression.analyses.r, v. 1.2) is downloadable from LMS_gh.</p>
<p>In order to identify the best potential biomarkers, we performed a matching of our regression analyses’ results. In this step, each univariable model was compared with its multivariable counterpart, and the models were considered matched when the analyzed genes and groups of tumors were the same, when both <em>p</em>-values were &lt;0.05, when both HR/OR values were either higher or lower than 1, and, concomitantly, when the discriminating capabilities of both models were good enough (AUC values &gt;0.65). Notably, in this paper, only the models that matched are presented.</p></section><section id="sec4dot6-ijms-25-10876"><h3 class="pmc_sec_title">4.6. Verification of Selected Polymorphisms</h3>
<p>In this study, the following selected genetic variants (with coordinates consistent with the hg38 human genome assembly) in 8 genes were verified by gradient PCR and Sanger sequencing: <em>MUTYH</em>, chr1:45332673del; <em>BRCA2</em>, chr17:43093093_43093096del; <em>FANCE</em>, chr6:g.35456000T&gt;G; <em>FANCI</em>, chr15:g.89295051C&gt;T; <em>FANCM</em>, chr14:g.45187852C&gt;G; <em>PRKDC</em>, chr8:g.47779009C&gt;T; <em>RAD51D</em>, chr17:g.35106436del; and <em>TP53</em>, chr17:g.7670658_7670659insA, COSV99037094. The PCR reactions employed either the AmpliTaq Gold™ DNA Polymerase (Thermo) or the Phusion Green High-Fidelity DNA Polymerase (Thermo)) and in-house-designed sets of primers (<a href="#app1-ijms-25-10876" class="usa-link">Table S3</a>). PCR products were analyzed by agarose gel electrophoresis using the Simply Safe reagent (EurX, Gdansk, Poland) for DNA visualization. Gels were documented on the UVP ChemStudio Imaging System (Analityk Jena, Jena, Germany). Afterward, specific PCR products of expected lengths were cleaned with ExoSAP-IT (Thermo) and sequenced using the appropriate primer and the BigDye Terminator v 3.1 Cycle Sequencing Kit (Thermo). Sanger sequencing products were then cleaned with the ExTerminator Kit (A&amp;A Biotechnology, Gdansk, Poland) and analyzed on the 3500 Genetic Analyzer (Thermo).</p></section><section id="sec4dot7-ijms-25-10876"><h3 class="pmc_sec_title">4.7. Protein Concentration Measurement</h3>
<p>Total protein lysates were obtained by incubating tumor samples with the RIPA buffer supplemented with the Halt Protease Inhibitor Cocktail (Thermo). Next, the concentration of each lysate was evaluated with the BCA assay (Sigma Aldrich, Saint Louis, MO, USA), using BSA (Thermo) in amounts ranging from 0 to 25 µg per well as a standard curve. The absorbance at 540 nm was measured on the Victor 3 spectrophotometer (model: 1420-012, Perkin Elmer, Waltham, MA, USA). The negative control wells, containing only the BCA solution, were used as blank samples in this experiment.</p></section><section id="sec4dot8-ijms-25-10876"><h3 class="pmc_sec_title">4.8. Western Blot (WB) Analyses</h3>
<p>WB analyses were performed for selected variants in genes coding for the TP53, NBN, CHEK1, CHEK2, FANCI, and FANCD2 proteins. Each WB experiment was preceded by WB tests confirming the specificity of the used primary antibodies (Abs). Except for lysates prepared from tumors, we also used a lysate prepared from a normal ovary as a control. For each experiment, 15–20 µg of a protein lysate was added per well. An electrophoretic separation of proteins was performed in 10–12% polyacrylamide gels (40% stock solution with the acrylamide to bis-acrylamide ratio equaling 37.5:1, BioRad, Hercules, CA, USA). To estimate the molecular weights of proteins, we used either the Broad Range Prestained Protein Marker (Proteintech, Rosemont, IL, USA) or the Precision Plus Protein Standard (BioRad). Depending on the protein being analyzed, either 0.2 μm nitrocellulose (Amersham™ Protran<sup>®</sup>, Cytiva, Marlborough, MA, USA) or 0.2 μm PVDF (Thermo) membranes were used. The transfer buffer was composed of 25 mM Tris (Sigma Aldrich), 192 mM Glycine (Sigma Aldrich), and 5–10% (<em>v</em>/<em>v</em>) methanol (Sigma Aldrich). Protein transfer was performed overnight (4 °C, 27 mA) or for 1–1.25 h (4 °C, 300 mA). For the membrane blocking, a 5% solution of skimmed milk (SM Gostyn, Gostyn, Poland) in the 1xTBST buffer (Tris-buffered saline (0.05 M Tris and 0.15 M NaCl) with 0.1% Tween-20 detergent (Sigma)) was used. As loading controls, Ponceau S red (Sigma Aldrich) staining, rabbit anti-β-actin Ab (1:100) (Thermo), and rabbit anti-vinculin Ab (1:500) (Thermo) were applied. Most primary Abs against selected proteins were purchased from Proteintech and were polyclonal antibodies developed in rabbits. By contrast, the primary mouse anti-TP53 antibody (Calbiochem, San Diego, CA, USA) was monoclonal. Chemiluminescence signals were detected on the UVP ChemStudio Imaging System (Analytik Jena, Jena, Germany) using either the goat anti-rabbit HRP-conjugated secondary Ab (Thermo) or the goat anti-mouse HRP-conjugated secondary Ab (Proteintech) and the SignalBright Max Chemiluminescent Substrate (Proteintech). A detailed description of the WB conditions for each protein is presented in <a href="#app1-ijms-25-10876" class="usa-link">Table S4</a>.</p></section></section><section id="sec5-ijms-25-10876"><h2 class="pmc_sec_title">5. Conclusions</h2>
<p>In this study, we examined the role of polymorphic variants in the most important oncogenes and suppressors in BOTS, lgOvCa, and hgOvCa. Our work contributes to the elucidation of the molecular landscape of various ovarian neoplasms, demonstrating completely divergent mutation profiles and molecular pathways engaged in their development. Certain mutations seem to play an important role in BOTS without the <em>BRAF</em> V600E variant (<em>KRAS</em>) and in lgOvCa (<em>KRAS</em> and <em>NRAS</em>), but not in hgOvCa, once again proving that advanced OvCa are molecularly distinct from less aggressive ovarian neoplasms. Additionally, based on multivariable regression analyses utilizing detailed clinicopathological data, potential biomarkers in BOTS (<em>PARP1</em>) and hgOvCa (<em>FANCI</em>, <em>BRCA2</em>, <em>TSC2</em>, <em>FANCF</em>) were identified. Noteworthy, for some of the analyzed genes, such as <em>FANCI</em>, <em>FANCD2</em>, and <em>FANCI</em>, <em>FANCF</em>, <em>TSC2</em>, the status of BRCA1/2 and TP53, respectively, turned out to be crucial. Although thorough mechanistic insight is necessary to fully investigate the molecular background of each genetic variant reported herein and to understand its clinical importance, still, our work sheds new light on the similarities and differences in the polymorphic patterns between ovarian tumors of diverse aggressiveness. Thus, it forms a valuable foundation for future research.</p></section><section id="app1-ijms-25-10876" class="app"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<p>The following supporting information can be downloaded at <a href="https://www.mdpi.com/article/10.3390/ijms252010876/s1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.mdpi.com/article/10.3390/ijms252010876/s1</a>.</p>
<section class="sm xbox font-sm" id="ijms-25-10876-s001"><div class="media p"><div class="caption">
<a href="/articles/instance/11507582/bin/ijms-25-10876-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">ijms-25-10876-s001.zip</a><sup> (12MB, zip) </sup>
</div></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization: L.A.S. and L.M.S.; data curation: L.A.S., P.S., J.K. and L.M.S.; formal analysis: L.A.S., J.K. and L.M.S.; funding acquisition: L.A.S. and L.M.S.; methodology: L.A.S. and L.M.S.; investigation: L.A.S. and A.D.-M.; visualization: L.A.S. and L.M.S.; resources: L.A.S., P.S. and J.K.; software: L.M.S.; supervision: L.M.S.; writing—original draft: L.A.S. and L.M.S.; writing—review and editing: P.S., A.D.-M. and J.K. All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Institutional Review Board Statement</h2>
<p>This study was conducted according to the guidelines of the Declaration of Helsinki and was approved in writing by the Institutional Review Board of the Maria Sklodowska-Curie National Research Institute of Oncology (nos. 49/2003 and 39/2007).</p></section><section id="notes3"><h2 class="pmc_sec_title">Informed Consent Statement</h2>
<p>Informed consent was obtained from all subjects involved in this study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>All data are available in the main text or <a href="#app1-ijms-25-10876" class="usa-link">Supplementary Materials</a>.</p></section><section id="notes5"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This research was funded by the Jakub Count Potocki Foundation, grant no. 657/19 (L.M.S.), the National Science Centre in Poland, grant no. 2020/37/B/NZ5/04215 (L.M.S.), and the Maria Sklodowska-Curie National Research Institute of Oncology, grant no. SN/MGW18/2024 (L.A.S.).</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Disclaimer/Publisher’s Note:</strong> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-ijms-25-10876">
<span class="label">1.</span><cite>Arora T., Mullangi S., Lekkala M.R.  Ovarian Cancer. StatPearls Publishing; Treasure Island, FL, USA: 2022. </cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/33620837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Ovarian%20Cancer&amp;author=T.%20Arora&amp;author=S.%20Mullangi&amp;author=M.R.%20Lekkala&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-ijms-25-10876">
<span class="label">2.</span><cite>Guo T., Dong X., Xie S., Zhang L., Zeng P., Zhang L. Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. CMAR. 2021;13:3081–3100. doi: 10.2147/CMAR.S292992.</cite> [<a href="https://doi.org/10.2147/CMAR.S292992" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8041604/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33854378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CMAR&amp;title=Cellular%20Mechanism%20of%20Gene%20Mutations%20and%20Potential%20Therapeutic%20Targets%20in%20Ovarian%20Cancer&amp;author=T.%20Guo&amp;author=X.%20Dong&amp;author=S.%20Xie&amp;author=L.%20Zhang&amp;author=P.%20Zeng&amp;volume=13&amp;publication_year=2021&amp;pages=3081-3100&amp;pmid=33854378&amp;doi=10.2147/CMAR.S292992&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-ijms-25-10876">
<span class="label">3.</span><cite>Babaier A., Mal H., Alselwi W., Ghatage P. Low-Grade Serous Carcinoma of the Ovary: The Current Status. Diagnostics. 2022;12:458.  doi: 10.3390/diagnostics12020458.</cite> [<a href="https://doi.org/10.3390/diagnostics12020458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8871133/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35204549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=Low-Grade%20Serous%20Carcinoma%20of%20the%20Ovary:%20The%20Current%20Status&amp;author=A.%20Babaier&amp;author=H.%20Mal&amp;author=W.%20Alselwi&amp;author=P.%20Ghatage&amp;volume=12&amp;publication_year=2022&amp;pages=458&amp;pmid=35204549&amp;doi=10.3390/diagnostics12020458&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-ijms-25-10876">
<span class="label">4.</span><cite>Wong K.-K., Bateman N.W., Ng C.W., Tsang Y.T.M., Sun C.S., Celestino J., Nguyen T.V., Malpica A., Hillman R.T., Zhang J., et al.  Integrated Multi-Omic Analysis of Low-Grade Ovarian Serous Carcinoma Collected from Short and Long-Term Survivors. J. Transl. Med. 2022;20:606. doi: 10.1186/s12967-022-03820-x.</cite> [<a href="https://doi.org/10.1186/s12967-022-03820-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9758924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36528667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Transl.%20Med.&amp;title=Integrated%20Multi-Omic%20Analysis%20of%20Low-Grade%20Ovarian%20Serous%20Carcinoma%20Collected%20from%20Short%20and%20Long-Term%20Survivors&amp;author=K.-K.%20Wong&amp;author=N.W.%20Bateman&amp;author=C.W.%20Ng&amp;author=Y.T.M.%20Tsang&amp;author=C.S.%20Sun&amp;volume=20&amp;publication_year=2022&amp;pages=606&amp;pmid=36528667&amp;doi=10.1186/s12967-022-03820-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5-ijms-25-10876">
<span class="label">5.</span><cite>Hauptmann S., Friedrich K., Redline R., Avril S. Ovarian Borderline Tumors in the 2014 WHO Classification: Evolving Concepts and Diagnostic Criteria. Virchows Arch. 2017;470:125–142. doi: 10.1007/s00428-016-2040-8.</cite> [<a href="https://doi.org/10.1007/s00428-016-2040-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5298321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28025670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Virchows%20Arch.&amp;title=Ovarian%20Borderline%20Tumors%20in%20the%202014%20WHO%20Classification:%20Evolving%20Concepts%20and%20Diagnostic%20Criteria&amp;author=S.%20Hauptmann&amp;author=K.%20Friedrich&amp;author=R.%20Redline&amp;author=S.%20Avril&amp;volume=470&amp;publication_year=2017&amp;pages=125-142&amp;pmid=28025670&amp;doi=10.1007/s00428-016-2040-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-ijms-25-10876">
<span class="label">6.</span><cite>Seong S.J., Kim D.H., Kim M.K., Song T. Controversies in Borderline Ovarian Tumors. J. Gynecol. Oncol. 2015;26:343–349. doi: 10.3802/jgo.2015.26.4.343.</cite> [<a href="https://doi.org/10.3802/jgo.2015.26.4.343" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4620372/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26404125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Gynecol.%20Oncol.&amp;title=Controversies%20in%20Borderline%20Ovarian%20Tumors&amp;author=S.J.%20Seong&amp;author=D.H.%20Kim&amp;author=M.K.%20Kim&amp;author=T.%20Song&amp;volume=26&amp;publication_year=2015&amp;pages=343-349&amp;pmid=26404125&amp;doi=10.3802/jgo.2015.26.4.343&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-ijms-25-10876">
<span class="label">7.</span><cite>Niu L., Tian H., Xu Y., Cao J., Zhang X., Zhang J., Hou J., Lv W., Wang J., Xin L., et al.  Recurrence Characteristics and Clinicopathological Results of Borderline Ovarian Tumors. BMC Women’s Health. 2021;21:134.  doi: 10.1186/s12905-021-01263-y.</cite> [<a href="https://doi.org/10.1186/s12905-021-01263-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8011410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33789656/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Women%E2%80%99s%20Health&amp;title=Recurrence%20Characteristics%20and%20Clinicopathological%20Results%20of%20Borderline%20Ovarian%20Tumors&amp;author=L.%20Niu&amp;author=H.%20Tian&amp;author=Y.%20Xu&amp;author=J.%20Cao&amp;author=X.%20Zhang&amp;volume=21&amp;publication_year=2021&amp;pages=134&amp;pmid=33789656&amp;doi=10.1186/s12905-021-01263-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-ijms-25-10876">
<span class="label">8.</span><cite>Shih K., Zhou Q., Huh J., Morgan J., Iasonos A., Aghajanian C., Chi D., Barakat R., Abu-Rustum N. Risk Factors for Recurrence of Ovarian Borderline Tumors. Gynecol. Oncol. 2011;120:480–484. doi: 10.1016/j.ygyno.2010.11.016.</cite> [<a href="https://doi.org/10.1016/j.ygyno.2010.11.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4843123/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21146201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.&amp;title=Risk%20Factors%20for%20Recurrence%20of%20Ovarian%20Borderline%20Tumors&amp;author=K.%20Shih&amp;author=Q.%20Zhou&amp;author=J.%20Huh&amp;author=J.%20Morgan&amp;author=A.%20Iasonos&amp;volume=120&amp;publication_year=2011&amp;pages=480-484&amp;pmid=21146201&amp;doi=10.1016/j.ygyno.2010.11.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-ijms-25-10876">
<span class="label">9.</span><cite>Bjørge T., Lie A.K., Hovig E., Gislefoss R.E., Hansen S., Jellum E., Langseth H., Nustad K., Tropé C.G., Dørum A. BRCA1 Mutations in Ovarian Cancer and Borderline Tumours in Norway: A Nested Case–Control Study. Br. J. Cancer. 2004;91:1829–1834. doi: 10.1038/sj.bjc.6602199.</cite> [<a href="https://doi.org/10.1038/sj.bjc.6602199" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2410048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15477862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Cancer&amp;title=BRCA1%20Mutations%20in%20Ovarian%20Cancer%20and%20Borderline%20Tumours%20in%20Norway:%20A%20Nested%20Case%E2%80%93Control%20Study&amp;author=T.%20Bj%C3%B8rge&amp;author=A.K.%20Lie&amp;author=E.%20Hovig&amp;author=R.E.%20Gislefoss&amp;author=S.%20Hansen&amp;volume=91&amp;publication_year=2004&amp;pages=1829-1834&amp;pmid=15477862&amp;doi=10.1038/sj.bjc.6602199&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-ijms-25-10876">
<span class="label">10.</span><cite>Lakhani S.R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., McGuffog L., Steele D., Devilee P., Klijn J.G.M., et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. Clin. Cancer Res. 2004;10:2473–2481. doi: 10.1158/1078-0432.CCR-1029-3.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-1029-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15073127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Pathology%20of%20Ovarian%20Cancers%20in%20BRCA1%20and%20BRCA2%20Carriers&amp;author=S.R.%20Lakhani&amp;author=S.%20Manek&amp;author=F.%20Penault-Llorca&amp;author=A.%20Flanagan&amp;author=L.%20Arnout&amp;volume=10&amp;publication_year=2004&amp;pages=2473-2481&amp;pmid=15073127&amp;doi=10.1158/1078-0432.CCR-1029-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-ijms-25-10876">
<span class="label">11.</span><cite>Singer G., Stöhr R., Cope L., Dehari R., Hartmann A., Cao D.-F., Wang T.-L., Kurman R.J., Shih I.-M. Patterns of P53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-Grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis with Immunohistochemical Correlation. Am. J. Surg. Pathol. 2005;29:218–224. doi: 10.1097/01.pas.0000146025.91953.8d.</cite> [<a href="https://doi.org/10.1097/01.pas.0000146025.91953.8d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15644779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Surg.%20Pathol.&amp;title=Patterns%20of%20P53%20Mutations%20Separate%20Ovarian%20Serous%20Borderline%20Tumors%20and%20Low-%20and%20High-Grade%20Carcinomas%20and%20Provide%20Support%20for%20a%20New%20Model%20of%20Ovarian%20Carcinogenesis:%20A%20Mutational%20Analysis%20with%20Immunohistochemical%20Correlation&amp;author=G.%20Singer&amp;author=R.%20St%C3%B6hr&amp;author=L.%20Cope&amp;author=R.%20Dehari&amp;author=A.%20Hartmann&amp;volume=29&amp;publication_year=2005&amp;pages=218-224&amp;pmid=15644779&amp;doi=10.1097/01.pas.0000146025.91953.8d&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-ijms-25-10876">
<span class="label">12.</span><cite>Mayr D., Hirschmann A., Löhrs U., Diebold J. KRAS and BRAF Mutations in Ovarian Tumors: A Comprehensive Study of Invasive Carcinomas, Borderline Tumors and Extraovarian Implants. Gynecol. Oncol. 2006;103:883–887. doi: 10.1016/j.ygyno.2006.05.029.</cite> [<a href="https://doi.org/10.1016/j.ygyno.2006.05.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16806438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.&amp;title=KRAS%20and%20BRAF%20Mutations%20in%20Ovarian%20Tumors:%20A%20Comprehensive%20Study%20of%20Invasive%20Carcinomas,%20Borderline%20Tumors%20and%20Extraovarian%20Implants&amp;author=D.%20Mayr&amp;author=A.%20Hirschmann&amp;author=U.%20L%C3%B6hrs&amp;author=J.%20Diebold&amp;volume=103&amp;publication_year=2006&amp;pages=883-887&amp;pmid=16806438&amp;doi=10.1016/j.ygyno.2006.05.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-ijms-25-10876">
<span class="label">13.</span><cite>Grisham R.N., Iyer G., Garg K., Delair D., Hyman D.M., Zhou Q., Iasonos A., Berger M.F., Dao F., Spriggs D.R., et al.  BRAF Mutation Is Associated with Early Stage Disease and Improved Outcome in Patients with Low-Grade Serous Ovarian Cancer. Cancer. 2013;119:548–554. doi: 10.1002/cncr.27782.</cite> [<a href="https://doi.org/10.1002/cncr.27782" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3961140/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22930283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=BRAF%20Mutation%20Is%20Associated%20with%20Early%20Stage%20Disease%20and%20Improved%20Outcome%20in%20Patients%20with%20Low-Grade%20Serous%20Ovarian%20Cancer&amp;author=R.N.%20Grisham&amp;author=G.%20Iyer&amp;author=K.%20Garg&amp;author=D.%20Delair&amp;author=D.M.%20Hyman&amp;volume=119&amp;publication_year=2013&amp;pages=548-554&amp;pmid=22930283&amp;doi=10.1002/cncr.27782&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-ijms-25-10876">
<span class="label">14.</span><cite>Stemke-Hale K., Shipman K., Kitsou-Mylona I., de Castro D.G., Hird V., Brown R., Flanagan J., Hani Gabra H., Mills G.B., Agarwal R., et al.  Frequency of Mutations and Polymorphisms in Borderline Ovarian Tumors of Known Cancer Genes. Mod. Pathol. 2013;26:544–552. doi: 10.1038/modpathol.2012.194.</cite> [<a href="https://doi.org/10.1038/modpathol.2012.194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3856435/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23174937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Frequency%20of%20Mutations%20and%20Polymorphisms%20in%20Borderline%20Ovarian%20Tumors%20of%20Known%20Cancer%20Genes&amp;author=K.%20Stemke-Hale&amp;author=K.%20Shipman&amp;author=I.%20Kitsou-Mylona&amp;author=D.G.%20de%20Castro&amp;author=V.%20Hird&amp;volume=26&amp;publication_year=2013&amp;pages=544-552&amp;pmid=23174937&amp;doi=10.1038/modpathol.2012.194&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-ijms-25-10876">
<span class="label">15.</span><cite>Ogrodniczak A., Menkiszak J., Gronwald J., Tomiczek-Szwiec J., Szwiec M., Cybulski C., Dębniak T., Huzarski T., Tołoczko-Grabarek A., Byrski T., et al.  Association of Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the Risk of Borderline Ovarian Tumor. Hered. Cancer Clin. Pract. 2022;20:11. doi: 10.1186/s13053-022-00218-0.</cite> [<a href="https://doi.org/10.1186/s13053-022-00218-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8935754/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35313928/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hered.%20Cancer%20Clin.%20Pract.&amp;title=Association%20of%20Recurrent%20Mutations%20in%20BRCA1,%20BRCA2,%20RAD51C,%20PALB2,%20and%20CHEK2%20with%20the%20Risk%20of%20Borderline%20Ovarian%20Tumor&amp;author=A.%20Ogrodniczak&amp;author=J.%20Menkiszak&amp;author=J.%20Gronwald&amp;author=J.%20Tomiczek-Szwiec&amp;author=M.%20Szwiec&amp;volume=20&amp;publication_year=2022&amp;pages=11&amp;pmid=35313928&amp;doi=10.1186/s13053-022-00218-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-ijms-25-10876">
<span class="label">16.</span><cite>Ko E.-A., Kim Y.-W., Lee D., Choi J., Kim S., Seo Y., Bang H., Kim J.-H., Ko J.-H. Expression of Potassium Channel Genes Predicts Clinical Outcome in Lung Cancer. Korean J. Physiol. Pharmacol. Off. J. Korean Physiol. Soc. Korean Soc. Pharmacol. 2019;23:529. doi: 10.4196/kjpp.2019.23.6.529.</cite> [<a href="https://doi.org/10.4196/kjpp.2019.23.6.529" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6819903/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31680775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Korean%20J.%20Physiol.%20Pharmacol.%20Off.%20J.%20Korean%20Physiol.%20Soc.%20Korean%20Soc.%20Pharmacol.&amp;title=Expression%20of%20Potassium%20Channel%20Genes%20Predicts%20Clinical%20Outcome%20in%20Lung%20Cancer&amp;author=E.-A.%20Ko&amp;author=Y.-W.%20Kim&amp;author=D.%20Lee&amp;author=J.%20Choi&amp;author=S.%20Kim&amp;volume=23&amp;publication_year=2019&amp;pages=529&amp;pmid=31680775&amp;doi=10.4196/kjpp.2019.23.6.529&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-ijms-25-10876">
<span class="label">17.</span><cite>Stelzer G., Rosen N., Plaschkes I., Zimmerman S., Twik M., Fishilevich S., Stein T.I., Nudel R., Lieder I., Mazor Y., et al.  The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr. Protoc. Bioinform. 2016;54:1.30.1–1.30.33. doi: 10.1002/cpbi.5.</cite> [<a href="https://doi.org/10.1002/cpbi.5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27322403/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr.%20Protoc.%20Bioinform.&amp;title=The%20GeneCards%20Suite:%20From%20Gene%20Data%20Mining%20to%20Disease%20Genome%20Sequence%20Analyses&amp;author=G.%20Stelzer&amp;author=N.%20Rosen&amp;author=I.%20Plaschkes&amp;author=S.%20Zimmerman&amp;author=M.%20Twik&amp;volume=54&amp;publication_year=2016&amp;pages=1.30.1-1.30.33&amp;pmid=27322403&amp;doi=10.1002/cpbi.5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-ijms-25-10876">
<span class="label">18.</span><cite>Szafron L.A., Iwanicka-Nowicka R., Podgorska A., Bonna A.M., Sobiczewski P., Kupryjanczyk J., Szafron L.M. The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors. Int. J. Mol. Sci. 2024;25:7531.  doi: 10.3390/ijms25147531.</cite> [<a href="https://doi.org/10.3390/ijms25147531" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11277161/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39062774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=The%20Clinical%20Significance%20of%20CRNDE%20Gene%20Methylation,%20Polymorphisms,%20and%20CRNDEP%20Micropeptide%20Expression%20in%20Ovarian%20Tumors&amp;author=L.A.%20Szafron&amp;author=R.%20Iwanicka-Nowicka&amp;author=A.%20Podgorska&amp;author=A.M.%20Bonna&amp;author=P.%20Sobiczewski&amp;volume=25&amp;publication_year=2024&amp;pages=7531&amp;pmid=39062774&amp;doi=10.3390/ijms25147531&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-ijms-25-10876">
<span class="label">19.</span><cite>Griffith O.L., Spies N.C., Anurag M., Griffith M., Luo J., Tu D., Yeo B., Kunisaki J., Miller C.A., Krysiak K., et al.  The Prognostic Effects of Somatic Mutations in ER-Positive Breast Cancer. Nat. Commun. 2018;9:3476. doi: 10.1038/s41467-018-05914-x.</cite> [<a href="https://doi.org/10.1038/s41467-018-05914-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6123466/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30181556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=The%20Prognostic%20Effects%20of%20Somatic%20Mutations%20in%20ER-Positive%20Breast%20Cancer&amp;author=O.L.%20Griffith&amp;author=N.C.%20Spies&amp;author=M.%20Anurag&amp;author=M.%20Griffith&amp;author=J.%20Luo&amp;volume=9&amp;publication_year=2018&amp;pages=3476&amp;pmid=30181556&amp;doi=10.1038/s41467-018-05914-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-ijms-25-10876">
<span class="label">20.</span><cite>Vias M., Morrill Gavarró L., Sauer C.M., Sanders D.A., Piskorz A.M., Couturier D.-L., Ballereau S., Hernando B., Schneider M.P., Hall J., et al.  High-Grade Serous Ovarian Carcinoma Organoids as Models of Chromosomal Instability. eLife. 2023;12:e83867. doi: 10.7554/eLife.83867.</cite> [<a href="https://doi.org/10.7554/eLife.83867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10174694/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37166279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=eLife&amp;title=High-Grade%20Serous%20Ovarian%20Carcinoma%20Organoids%20as%20Models%20of%20Chromosomal%20Instability&amp;author=M.%20Vias&amp;author=L.%20Morrill%20Gavarr%C3%B3&amp;author=C.M.%20Sauer&amp;author=D.A.%20Sanders&amp;author=A.M.%20Piskorz&amp;volume=12&amp;publication_year=2023&amp;pages=e83867&amp;pmid=37166279&amp;doi=10.7554/eLife.83867&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-ijms-25-10876">
<span class="label">21.</span><cite>Smith P., Bradley T., Gavarró L.M., Goranova T., Ennis D.P., Mirza H.B., De Silva D., Piskorz A.M., Sauer C.M., Al-Khalidi S., et al.  The Copy Number and Mutational Landscape of Recurrent Ovarian High-Grade Serous Carcinoma. Nat. Commun. 2023;14:4387. doi: 10.1038/s41467-023-39867-7.</cite> [<a href="https://doi.org/10.1038/s41467-023-39867-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10359414/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37474499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=The%20Copy%20Number%20and%20Mutational%20Landscape%20of%20Recurrent%20Ovarian%20High-Grade%20Serous%20Carcinoma&amp;author=P.%20Smith&amp;author=T.%20Bradley&amp;author=L.M.%20Gavarr%C3%B3&amp;author=T.%20Goranova&amp;author=D.P.%20Ennis&amp;volume=14&amp;publication_year=2023&amp;pages=4387&amp;pmid=37474499&amp;doi=10.1038/s41467-023-39867-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-ijms-25-10876">
<span class="label">22.</span><cite>Kupryjanczyk J., Bell D.A., Dimeo D., Beauchamp R., Thor A.D., Yandell D.W. P53 Gene Analysis of Ovarian Borderline Tumors and Stage I Carcinomas. Hum. Pathol. 1995;26:387–392. doi: 10.1016/0046-8177(95)90138-8.</cite> [<a href="https://doi.org/10.1016/0046-8177(95)90138-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7705816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum.%20Pathol.&amp;title=P53%20Gene%20Analysis%20of%20Ovarian%20Borderline%20Tumors%20and%20Stage%20I%20Carcinomas&amp;author=J.%20Kupryjanczyk&amp;author=D.A.%20Bell&amp;author=D.%20Dimeo&amp;author=R.%20Beauchamp&amp;author=A.D.%20Thor&amp;volume=26&amp;publication_year=1995&amp;pages=387-392&amp;pmid=7705816&amp;doi=10.1016/0046-8177(95)90138-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-ijms-25-10876">
<span class="label">23.</span><cite>Katabuchi H., Tashiro H., Cho K.R., Kurman R.J., Hedrick Ellenson L. Micropapillary Serous Carcinoma of the Ovary: An Immunohistochemical and Mutational Analysis of P53. Int. J. Gynecol. Pathol. 1998;17:54–60. doi: 10.1097/00004347-199801000-00010.</cite> [<a href="https://doi.org/10.1097/00004347-199801000-00010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9475193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Gynecol.%20Pathol.&amp;title=Micropapillary%20Serous%20Carcinoma%20of%20the%20Ovary:%20An%20Immunohistochemical%20and%20Mutational%20Analysis%20of%20P53&amp;author=H.%20Katabuchi&amp;author=H.%20Tashiro&amp;author=K.R.%20Cho&amp;author=R.J.%20Kurman&amp;author=L.%20Hedrick%20Ellenson&amp;volume=17&amp;publication_year=1998&amp;pages=54-60&amp;pmid=9475193&amp;doi=10.1097/00004347-199801000-00010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-ijms-25-10876">
<span class="label">24.</span><cite>Testa U., Petrucci E., Pasquini L., Castelli G., Pelosi E. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines. 2018;5:16.  doi: 10.3390/medicines5010016.</cite> [<a href="https://doi.org/10.3390/medicines5010016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5874581/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29389895/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicines&amp;title=Ovarian%20Cancers:%20Genetic%20Abnormalities,%20Tumor%20Heterogeneity%20and%20Progression,%20Clonal%20Evolution%20and%20Cancer%20Stem%20Cells&amp;author=U.%20Testa&amp;author=E.%20Petrucci&amp;author=L.%20Pasquini&amp;author=G.%20Castelli&amp;author=E.%20Pelosi&amp;volume=5&amp;publication_year=2018&amp;pages=16&amp;pmid=29389895&amp;doi=10.3390/medicines5010016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-ijms-25-10876">
<span class="label">25.</span><cite>KAPA HyperPETE.  [(accessed on 7 June 2024)].  Available online:  <a href="https://sequencing.roche.com/us/en/products/product-category/primer-extension-based-target-enrichment.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://sequencing.roche.com/us/en/products/product-category/primer-extension-based-target-enrichment.html</a>.</cite>
</li>
<li id="B26-ijms-25-10876">
<span class="label">26.</span><cite>Kang E.Y., Cheasley D., LePage C., Wakefield M.J., da Cunha Torres M., Rowley S., Salazar C., Xing Z., Allan P., Bowtell D.D.L., et al.  Refined Cut-off for TP53 Immunohistochemistry Improves Prediction of TP53 Mutation Status in Ovarian Mucinous Tumors: Implications for Outcome Analyses. Mod. Pathol. 2021;34:194–206. doi: 10.1038/s41379-020-0618-9.</cite> [<a href="https://doi.org/10.1038/s41379-020-0618-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9704519/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32724153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Refined%20Cut-off%20for%20TP53%20Immunohistochemistry%20Improves%20Prediction%20of%20TP53%20Mutation%20Status%20in%20Ovarian%20Mucinous%20Tumors:%20Implications%20for%20Outcome%20Analyses&amp;author=E.Y.%20Kang&amp;author=D.%20Cheasley&amp;author=C.%20LePage&amp;author=M.J.%20Wakefield&amp;author=M.%20da%20Cunha%20Torres&amp;volume=34&amp;publication_year=2021&amp;pages=194-206&amp;pmid=32724153&amp;doi=10.1038/s41379-020-0618-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-ijms-25-10876">
<span class="label">27.</span><cite>Kupryjańczyk J., Szymańska T., Madry R., Timorek A., Stelmachów J., Karpińska G., Rembiszewska A., Ziółkowska I., Kraszewska E., Debniak J., et al.  Evaluation of Clinical Significance of TP53, BCL-2, BAX and MEK1 Expression in 229 Ovarian Carcinomas Treated with Platinum-Based Regimen. Br. J. Cancer. 2003;88:848–854. doi: 10.1038/sj.bjc.6600789.</cite> [<a href="https://doi.org/10.1038/sj.bjc.6600789" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2377076/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12644821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Cancer&amp;title=Evaluation%20of%20Clinical%20Significance%20of%20TP53,%20BCL-2,%20BAX%20and%20MEK1%20Expression%20in%20229%20Ovarian%20Carcinomas%20Treated%20with%20Platinum-Based%20Regimen&amp;author=J.%20Kupryja%C5%84czyk&amp;author=T.%20Szyma%C5%84ska&amp;author=R.%20Madry&amp;author=A.%20Timorek&amp;author=J.%20Stelmach%C3%B3w&amp;volume=88&amp;publication_year=2003&amp;pages=848-854&amp;pmid=12644821&amp;doi=10.1038/sj.bjc.6600789&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-ijms-25-10876">
<span class="label">28.</span><cite>Ghezelayagh T.S., Pennington K.P., Norquist B.M., Khasnavis N., Radke M.R., Kilgore M.R., Garcia R.L., Lee M., Katz R., Leslie K.K., et al.  Characterizing TP53 Mutations in Ovarian Carcinomas with and without Concurrent BRCA1 or BRCA2 Mutations. Gynecol. Oncol. 2021;160:786–792. doi: 10.1016/j.ygyno.2020.12.007.</cite> [<a href="https://doi.org/10.1016/j.ygyno.2020.12.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8491988/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33375991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.&amp;title=Characterizing%20TP53%20Mutations%20in%20Ovarian%20Carcinomas%20with%20and%20without%20Concurrent%20BRCA1%20or%20BRCA2%20Mutations&amp;author=T.S.%20Ghezelayagh&amp;author=K.P.%20Pennington&amp;author=B.M.%20Norquist&amp;author=N.%20Khasnavis&amp;author=M.R.%20Radke&amp;volume=160&amp;publication_year=2021&amp;pages=786-792&amp;pmid=33375991&amp;doi=10.1016/j.ygyno.2020.12.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29-ijms-25-10876">
<span class="label">29.</span><cite>Lhotova K., Stolarova L., Zemankova P., Vocka M., Janatova M., Borecka M., Cerna M., Jelinkova S., Kral J., Volkova Z., et al.  Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers. 2020;12:956.  doi: 10.3390/cancers12040956.</cite> [<a href="https://doi.org/10.3390/cancers12040956" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7226062/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32295079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Multigene%20Panel%20Germline%20Testing%20of%201333%20Czech%20Patients%20with%20Ovarian%20Cancer&amp;author=K.%20Lhotova&amp;author=L.%20Stolarova&amp;author=P.%20Zemankova&amp;author=M.%20Vocka&amp;author=M.%20Janatova&amp;volume=12&amp;publication_year=2020&amp;pages=956&amp;pmid=32295079&amp;doi=10.3390/cancers12040956&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-ijms-25-10876">
<span class="label">30.</span><cite>Flis M., Krawczyk P., Drogoń I., Kurek K., Kieszko R., Milanowski J. The Effectiveness of Chemotherapy in Small Cell Lung Cancer Patients with BRCA2 Gene Mutation and Schwartz-Bartter Syndrome. Oncol. Clin. Pr. 2019;15:120–123. doi: 10.5603/OCP.2019.0008.</cite> [<a href="https://doi.org/10.5603/OCP.2019.0008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncol.%20Clin.%20Pr.&amp;title=The%20Effectiveness%20of%20Chemotherapy%20in%20Small%20Cell%20Lung%20Cancer%20Patients%20with%20BRCA2%20Gene%20Mutation%20and%20Schwartz-Bartter%20Syndrome&amp;author=M.%20Flis&amp;author=P.%20Krawczyk&amp;author=I.%20Drogo%C5%84&amp;author=K.%20Kurek&amp;author=R.%20Kieszko&amp;volume=15&amp;publication_year=2019&amp;pages=120-123&amp;doi=10.5603/OCP.2019.0008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-ijms-25-10876">
<span class="label">31.</span><cite>Mylavarapu S., Das A., Roy M. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. Front. Oncol. 2018;8:16.  doi: 10.3389/fonc.2018.00016.</cite> [<a href="https://doi.org/10.3389/fonc.2018.00016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5807680/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29459887/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Role%20of%20BRCA%20Mutations%20in%20the%20Modulation%20of%20Response%20to%20Platinum%20Therapy&amp;author=S.%20Mylavarapu&amp;author=A.%20Das&amp;author=M.%20Roy&amp;volume=8&amp;publication_year=2018&amp;pages=16&amp;pmid=29459887&amp;doi=10.3389/fonc.2018.00016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32-ijms-25-10876">
<span class="label">32.</span><cite>Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: Different Roles in a Common Pathway of Genome Protection. Nat. Rev. Cancer. 2011;12:68–78. doi: 10.1038/nrc3181.</cite> [<a href="https://doi.org/10.1038/nrc3181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4972490/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22193408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Cancer&amp;title=BRCA1%20and%20BRCA2:%20Different%20Roles%20in%20a%20Common%20Pathway%20of%20Genome%20Protection&amp;author=R.%20Roy&amp;author=J.%20Chun&amp;author=S.N.%20Powell&amp;volume=12&amp;publication_year=2011&amp;pages=68-78&amp;pmid=22193408&amp;doi=10.1038/nrc3181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-ijms-25-10876">
<span class="label">33.</span><cite>Moujaber T., Etemadmoghadam D., Kennedy C.J., Chiew Y.-E., Balleine R.L., Saunders C., Wain G.V., Gao B., Hogg R., Srirangan S., et al.  BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precis. Oncol. 2018;2:1–14. doi: 10.1200/PO.17.00221.</cite> [<a href="https://doi.org/10.1200/PO.17.00221" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35135122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precis.%20Oncol.&amp;title=BRAF%20Mutations%20in%20Low-Grade%20Serous%20Ovarian%20Cancer%20and%20Response%20to%20BRAF%20Inhibition&amp;author=T.%20Moujaber&amp;author=D.%20Etemadmoghadam&amp;author=C.J.%20Kennedy&amp;author=Y.-E.%20Chiew&amp;author=R.L.%20Balleine&amp;volume=2&amp;publication_year=2018&amp;pages=1-14&amp;pmid=35135122&amp;doi=10.1200/PO.17.00221&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-ijms-25-10876">
<span class="label">34.</span><cite>Auner V., Kriegshäuser G., Tong D., Horvat R., Reinthaller A., Mustea A., Zeillinger R. KRAS Mutation Analysis in Ovarian Samples Using a High Sensitivity Biochip Assay. BMC Cancer. 2009;9:111.  doi: 10.1186/1471-2407-9-111.</cite> [<a href="https://doi.org/10.1186/1471-2407-9-111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2671522/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19358724/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=KRAS%20Mutation%20Analysis%20in%20Ovarian%20Samples%20Using%20a%20High%20Sensitivity%20Biochip%20Assay&amp;author=V.%20Auner&amp;author=G.%20Kriegsh%C3%A4user&amp;author=D.%20Tong&amp;author=R.%20Horvat&amp;author=A.%20Reinthaller&amp;volume=9&amp;publication_year=2009&amp;pages=111&amp;pmid=19358724&amp;doi=10.1186/1471-2407-9-111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-ijms-25-10876">
<span class="label">35.</span><cite>Garziera M., Roncato R., Montico M., De Mattia E., Gagno S., Poletto E., Scalone S., Canzonieri V., Giorda G., Sorio R., et al.  New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. Cells. 2019;8:584.  doi: 10.3390/cells8060584.</cite> [<a href="https://doi.org/10.3390/cells8060584" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6627128/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31197119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=New%20Challenges%20in%20Tumor%20Mutation%20Heterogeneity%20in%20Advanced%20Ovarian%20Cancer%20by%20a%20Targeted%20Next-Generation%20Sequencing%20(NGS)%20Approach&amp;author=M.%20Garziera&amp;author=R.%20Roncato&amp;author=M.%20Montico&amp;author=E.%20De%20Mattia&amp;author=S.%20Gagno&amp;volume=8&amp;publication_year=2019&amp;pages=584&amp;pmid=31197119&amp;doi=10.3390/cells8060584&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-ijms-25-10876">
<span class="label">36.</span><cite>Mutations in the KRAS Gene in Ovarian Tumors—PubMed.  [(accessed on 14 January 2024)]; Available online:  <a href="https://pubmed.ncbi.nlm.nih.gov/19995707/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/19995707/</a></cite>
</li>
<li id="B37-ijms-25-10876">
<span class="label">37.</span><cite>Merz V., Gaule M., Zecchetto C., Cavaliere A., Casalino S., Pesoni C., Contarelli S., Sabbadini F., Bertolini M., Mangiameli D., et al.  Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Front. Oncol. 2021;11:638360.  doi: 10.3389/fonc.2021.638360.</cite> [<a href="https://doi.org/10.3389/fonc.2021.638360" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7991835/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33777798/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Targeting%20KRAS:%20The%20Elephant%20in%20the%20Room%20of%20Epithelial%20Cancers&amp;author=V.%20Merz&amp;author=M.%20Gaule&amp;author=C.%20Zecchetto&amp;author=A.%20Cavaliere&amp;author=S.%20Casalino&amp;volume=11&amp;publication_year=2021&amp;pages=638360&amp;pmid=33777798&amp;doi=10.3389/fonc.2021.638360&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-ijms-25-10876">
<span class="label">38.</span><cite>Zhu C., Guan X., Zhang X., Luan X., Song Z., Cheng X., Zhang W., Qin J.-J. Targeting KRAS Mutant Cancers: From Druggable Therapy to Drug Resistance. Mol. Cancer. 2022;21:159. doi: 10.1186/s12943-022-01629-2.</cite> [<a href="https://doi.org/10.1186/s12943-022-01629-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9351107/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35922812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cancer&amp;title=Targeting%20KRAS%20Mutant%20Cancers:%20From%20Druggable%20Therapy%20to%20Drug%20Resistance&amp;author=C.%20Zhu&amp;author=X.%20Guan&amp;author=X.%20Zhang&amp;author=X.%20Luan&amp;author=Z.%20Song&amp;volume=21&amp;publication_year=2022&amp;pages=159&amp;pmid=35922812&amp;doi=10.1186/s12943-022-01629-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-ijms-25-10876">
<span class="label">39.</span><cite>Śmiech M., Leszczyński P., Kono H., Wardell C., Taniguchi H. Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes. 2020;11:1342.  doi: 10.3390/genes11111342.</cite> [<a href="https://doi.org/10.3390/genes11111342" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7697059/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33198372/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes&amp;title=Emerging%20BRAF%20Mutations%20in%20Cancer%20Progression%20and%20Their%20Possible%20Effects%20on%20Transcriptional%20Networks&amp;author=M.%20%C5%9Amiech&amp;author=P.%20Leszczy%C5%84ski&amp;author=H.%20Kono&amp;author=C.%20Wardell&amp;author=H.%20Taniguchi&amp;volume=11&amp;publication_year=2020&amp;pages=1342&amp;pmid=33198372&amp;doi=10.3390/genes11111342&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-ijms-25-10876">
<span class="label">40.</span><cite>Hunter S.M., Anglesio M.S., Ryland G.L., Sharma R., Chiew Y.-E., Rowley S.M., Doyle M.A., Li J., Gilks C.B., Moss P., et al.  Molecular Profiling of Low Grade Serous Ovarian Tumours Identifies Novel Candidate Driver Genes. Oncotarget. 2015;6:37663–37677. doi: 10.18632/oncotarget.5438.</cite> [<a href="https://doi.org/10.18632/oncotarget.5438" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4741956/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26506417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Molecular%20Profiling%20of%20Low%20Grade%20Serous%20Ovarian%20Tumours%20Identifies%20Novel%20Candidate%20Driver%20Genes&amp;author=S.M.%20Hunter&amp;author=M.S.%20Anglesio&amp;author=G.L.%20Ryland&amp;author=R.%20Sharma&amp;author=Y.-E.%20Chiew&amp;volume=6&amp;publication_year=2015&amp;pages=37663-37677&amp;pmid=26506417&amp;doi=10.18632/oncotarget.5438&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B41-ijms-25-10876">
<span class="label">41.</span><cite>Xing D., Suryo Rahmanto Y., Zeppernick F., Hannibal C.G., Kjaer S.K., Vang R., Shih I.-M., Wang T.-L. Mutation of NRAS Is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma. Hum. Pathol. 2017;68:87–91. doi: 10.1016/j.humpath.2017.08.021.</cite> [<a href="https://doi.org/10.1016/j.humpath.2017.08.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5696063/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28873354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum.%20Pathol.&amp;title=Mutation%20of%20NRAS%20Is%20a%20Rare%20Genetic%20Event%20in%20Ovarian%20Low-Grade%20Serous%20Carcinoma&amp;author=D.%20Xing&amp;author=Y.%20Suryo%20Rahmanto&amp;author=F.%20Zeppernick&amp;author=C.G.%20Hannibal&amp;author=S.K.%20Kjaer&amp;volume=68&amp;publication_year=2017&amp;pages=87-91&amp;pmid=28873354&amp;doi=10.1016/j.humpath.2017.08.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B42-ijms-25-10876">
<span class="label">42.</span><cite>Champer M., Miller D., Kuo D.Y.-S. Response to Trametinib in Recurrent Low-Grade Serous Ovarian Cancer with NRAS Mutation: A Case Report. Gynecol. Oncol. Rep. 2019;28:26–28. doi: 10.1016/j.gore.2019.01.007.</cite> [<a href="https://doi.org/10.1016/j.gore.2019.01.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6374783/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30809568/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.%20Rep.&amp;title=Response%20to%20Trametinib%20in%20Recurrent%20Low-Grade%20Serous%20Ovarian%20Cancer%20with%20NRAS%20Mutation:%20A%20Case%20Report&amp;author=M.%20Champer&amp;author=D.%20Miller&amp;author=D.Y.-S.%20Kuo&amp;volume=28&amp;publication_year=2019&amp;pages=26-28&amp;pmid=30809568&amp;doi=10.1016/j.gore.2019.01.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B43-ijms-25-10876">
<span class="label">43.</span><cite>Grill C., Larue L. NRAS, NRAS, Which Mutation Is Fairest of Them All? J. Investig. Dermatol. 2016;136:1936–1938. doi: 10.1016/j.jid.2016.06.011.</cite> [<a href="https://doi.org/10.1016/j.jid.2016.06.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27664710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Investig.%20Dermatol.&amp;title=NRAS,%20NRAS,%20Which%20Mutation%20Is%20Fairest%20of%20Them%20All?&amp;author=C.%20Grill&amp;author=L.%20Larue&amp;volume=136&amp;publication_year=2016&amp;pages=1936-1938&amp;pmid=27664710&amp;doi=10.1016/j.jid.2016.06.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B44-ijms-25-10876">
<span class="label">44.</span><cite>McCluggage W.G. Ovarian Borderline Tumours: A Review with Comparison of Serous and Mucinous Types. Diagn. Histopathol. 2014;20:333–350. doi: 10.1016/j.mpdhp.2014.07.001.</cite> [<a href="https://doi.org/10.1016/j.mpdhp.2014.07.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagn.%20Histopathol.&amp;title=Ovarian%20Borderline%20Tumours:%20A%20Review%20with%20Comparison%20of%20Serous%20and%20Mucinous%20Types&amp;author=W.G.%20McCluggage&amp;volume=20&amp;publication_year=2014&amp;pages=333-350&amp;doi=10.1016/j.mpdhp.2014.07.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B45-ijms-25-10876">
<span class="label">45.</span><cite>Zhong F., Zhu T., Pan X., Zhang Y., Yang H., Wang X., Hu J., Han H., Mei L., Chen D., et al.  Comprehensive Genomic Profiling of High-grade Serous Ovarian Carcinoma from Chinese Patients Identifies Co-occurring Mutations in the Ras/Raf Pathway with TP53. Cancer Med. 2019;8:3928–3935. doi: 10.1002/cam4.2243.</cite> [<a href="https://doi.org/10.1002/cam4.2243" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6639185/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31124283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med.&amp;title=Comprehensive%20Genomic%20Profiling%20of%20High-grade%20Serous%20Ovarian%20Carcinoma%20from%20Chinese%20Patients%20Identifies%20Co-occurring%20Mutations%20in%20the%20Ras/Raf%20Pathway%20with%20TP53&amp;author=F.%20Zhong&amp;author=T.%20Zhu&amp;author=X.%20Pan&amp;author=Y.%20Zhang&amp;author=H.%20Yang&amp;volume=8&amp;publication_year=2019&amp;pages=3928-3935&amp;pmid=31124283&amp;doi=10.1002/cam4.2243&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B46-ijms-25-10876">
<span class="label">46.</span><cite>Bożyk A., Krawczyk P., Reszka K., Krukowska K., Kolak A., Mańdziuk S., Wojas-Krawczyk K., Ramlau R., Milanowski J. Correlation between KRAS, NRAS and BRAF Mutations and Tumor Localizations in Patients with Primary and Metastatic Colorectal Cancer. Arch. Med. Sci. AMS. 2022;18:1221–1230. doi: 10.5114/aoms/109170.</cite> [<a href="https://doi.org/10.5114/aoms/109170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9479594/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36160343/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch.%20Med.%20Sci.%20AMS&amp;title=Correlation%20between%20KRAS,%20NRAS%20and%20BRAF%20Mutations%20and%20Tumor%20Localizations%20in%20Patients%20with%20Primary%20and%20Metastatic%20Colorectal%20Cancer&amp;author=A.%20Bo%C5%BCyk&amp;author=P.%20Krawczyk&amp;author=K.%20Reszka&amp;author=K.%20Krukowska&amp;author=A.%20Kolak&amp;volume=18&amp;publication_year=2022&amp;pages=1221-1230&amp;pmid=36160343&amp;doi=10.5114/aoms/109170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B47-ijms-25-10876">
<span class="label">47.</span><cite>Alessandro L., Low K.-J.E., Abushelaibi A., Lim S.-H.E., Cheng W.-H., Chang S.-K., Lai K.-S., Sum Y.W., Maran S. Identification of NRAS Diagnostic Biomarkers and Drug Targets for Endometrial Cancer-An Integrated in Silico Approach. Int. J. Mol. Sci. 2022;23:14285.  doi: 10.3390/ijms232214285.</cite> [<a href="https://doi.org/10.3390/ijms232214285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9692821/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36430761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Identification%20of%20NRAS%20Diagnostic%20Biomarkers%20and%20Drug%20Targets%20for%20Endometrial%20Cancer-An%20Integrated%20in%20Silico%20Approach&amp;author=L.%20Alessandro&amp;author=K.-J.E.%20Low&amp;author=A.%20Abushelaibi&amp;author=S.-H.E.%20Lim&amp;author=W.-H.%20Cheng&amp;volume=23&amp;publication_year=2022&amp;pages=14285&amp;pmid=36430761&amp;doi=10.3390/ijms232214285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B48-ijms-25-10876">
<span class="label">48.</span><cite>Sideris M., Emin E.I., Abdullah Z., Hanrahan J., Stefatou K.M., Sevas V., Emin E., Hollingworth T., Odejinmi F., Papagrigoriadis S., et al.  The Role of KRAS in Endometrial Cancer: A Mini-Review. Anticancer Res. 2019;39:533–539. doi: 10.21873/anticanres.13145.</cite> [<a href="https://doi.org/10.21873/anticanres.13145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30711927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res.&amp;title=The%20Role%20of%20KRAS%20in%20Endometrial%20Cancer:%20A%20Mini-Review&amp;author=M.%20Sideris&amp;author=E.I.%20Emin&amp;author=Z.%20Abdullah&amp;author=J.%20Hanrahan&amp;author=K.M.%20Stefatou&amp;volume=39&amp;publication_year=2019&amp;pages=533-539&amp;pmid=30711927&amp;doi=10.21873/anticanres.13145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B49-ijms-25-10876">
<span class="label">49.</span><cite>He M., Breese V., Hang S., Zhang C., Xiong J., Jackson C. BRAF V600E Mutations in Endometrial Adenocarcinoma. Diagn. Mol. Pathol. Am. J. Surg. Pathol. Part B. 2013;22:35–40. doi: 10.1097/PDM.0b013e31826c7fe0.</cite> [<a href="https://doi.org/10.1097/PDM.0b013e31826c7fe0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23370429/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagn.%20Mol.%20Pathol.%20Am.%20J.%20Surg.%20Pathol.%20Part%20B&amp;title=BRAF%20V600E%20Mutations%20in%20Endometrial%20Adenocarcinoma&amp;author=M.%20He&amp;author=V.%20Breese&amp;author=S.%20Hang&amp;author=C.%20Zhang&amp;author=J.%20Xiong&amp;volume=22&amp;publication_year=2013&amp;pages=35-40&amp;pmid=23370429&amp;doi=10.1097/PDM.0b013e31826c7fe0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B50-ijms-25-10876">
<span class="label">50.</span><cite>Gianni P., Matenoglou E., Geropoulos G., Agrawal N., Adnani H., Zafeiropoulos S., Miyara S.J., Guevara S., Mumford J.M., Molmenti E.P., et al.  The Fanconi Anemia Pathway and Breast Cancer: A Comprehensive Review of Clinical Data. Clin. Breast Cancer. 2022;22:10–25. doi: 10.1016/j.clbc.2021.08.001.</cite> [<a href="https://doi.org/10.1016/j.clbc.2021.08.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34489172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Breast%20Cancer&amp;title=The%20Fanconi%20Anemia%20Pathway%20and%20Breast%20Cancer:%20A%20Comprehensive%20Review%20of%20Clinical%20Data&amp;author=P.%20Gianni&amp;author=E.%20Matenoglou&amp;author=G.%20Geropoulos&amp;author=N.%20Agrawal&amp;author=H.%20Adnani&amp;volume=22&amp;publication_year=2022&amp;pages=10-25&amp;pmid=34489172&amp;doi=10.1016/j.clbc.2021.08.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B51-ijms-25-10876">
<span class="label">51.</span><cite>Del Valle J., Rofes P., Moreno-Cabrera J.M., López-Dóriga A., Belhadj S., Vargas-Parra G., Teulé À., Cuesta R., Muñoz X., Campos O., et al.  Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients. Cancers. 2020;12:829.  doi: 10.3390/cancers12040829.</cite> [<a href="https://doi.org/10.3390/cancers12040829" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7226125/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32235514/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Exploring%20the%20Role%20of%20Mutations%20in%20Fanconi%20Anemia%20Genes%20in%20Hereditary%20Cancer%20Patients&amp;author=J.%20Del%20Valle&amp;author=P.%20Rofes&amp;author=J.M.%20Moreno-Cabrera&amp;author=A.%20L%C3%B3pez-D%C3%B3riga&amp;author=S.%20Belhadj&amp;volume=12&amp;publication_year=2020&amp;pages=829&amp;pmid=32235514&amp;doi=10.3390/cancers12040829&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B52-ijms-25-10876">
<span class="label">52.</span><cite>Gajewski S., Hartwig A. PARP1 Is Required for ATM-Mediated P53 Activation and P53-Mediated Gene Expression after Ionizing Radiation. Chem. Res. Toxicol. 2020;33:1933–1940. doi: 10.1021/acs.chemrestox.0c00130.</cite> [<a href="https://doi.org/10.1021/acs.chemrestox.0c00130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32551582/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem.%20Res.%20Toxicol.&amp;title=PARP1%20Is%20Required%20for%20ATM-Mediated%20P53%20Activation%20and%20P53-Mediated%20Gene%20Expression%20after%20Ionizing%20Radiation&amp;author=S.%20Gajewski&amp;author=A.%20Hartwig&amp;volume=33&amp;publication_year=2020&amp;pages=1933-1940&amp;pmid=32551582&amp;doi=10.1021/acs.chemrestox.0c00130&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B53-ijms-25-10876">
<span class="label">53.</span><cite>Zuo W.-W., Zhao C.-F., Li Y., Sun H.-Y., Ma G.-M., Liu Y.-P., Kang S. High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer. Front. Oncol. 2022;12:931445.  doi: 10.3389/fonc.2022.931445.</cite> [<a href="https://doi.org/10.3389/fonc.2022.931445" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9301997/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35875162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=High%20Expression%20of%20PARP1%20in%20Tumor%20and%20Stroma%20Cells%20Predicts%20Different%20Prognosis%20and%20Platinum%20Resistance%20in%20Patients%20With%20Advanced%20Epithelial%20Ovarian%20Cancer&amp;author=W.-W.%20Zuo&amp;author=C.-F.%20Zhao&amp;author=Y.%20Li&amp;author=H.-Y.%20Sun&amp;author=G.-M.%20Ma&amp;volume=12&amp;publication_year=2022&amp;pages=931445&amp;pmid=35875162&amp;doi=10.3389/fonc.2022.931445&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B54-ijms-25-10876">
<span class="label">54.</span><cite>Hockings H., Miller R.E. The Role of PARP Inhibitor Combination Therapy in Ovarian Cancer. Ther. Adv. Med. Oncol. 2023;15:17588359231173183. doi: 10.1177/17588359231173183.</cite> [<a href="https://doi.org/10.1177/17588359231173183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10196552/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37215065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther.%20Adv.%20Med.%20Oncol.&amp;title=The%20Role%20of%20PARP%20Inhibitor%20Combination%20Therapy%20in%20Ovarian%20Cancer&amp;author=H.%20Hockings&amp;author=R.E.%20Miller&amp;volume=15&amp;publication_year=2023&amp;pages=17588359231173183&amp;pmid=37215065&amp;doi=10.1177/17588359231173183&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B55-ijms-25-10876">
<span class="label">55.</span><cite>Miller R.E., El-Shakankery K.H., Lee J.-Y. PARP Inhibitors in Ovarian Cancer: Overcoming Resistance with Combination Strategies. J. Gynecol. Oncol. 2022;33:e44. doi: 10.3802/jgo.2022.33.e44.</cite> [<a href="https://doi.org/10.3802/jgo.2022.33.e44" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9024188/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35320891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Gynecol.%20Oncol.&amp;title=PARP%20Inhibitors%20in%20Ovarian%20Cancer:%20Overcoming%20Resistance%20with%20Combination%20Strategies&amp;author=R.E.%20Miller&amp;author=K.H.%20El-Shakankery&amp;author=J.-Y.%20Lee&amp;volume=33&amp;publication_year=2022&amp;pages=e44&amp;pmid=35320891&amp;doi=10.3802/jgo.2022.33.e44&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B56-ijms-25-10876">
<span class="label">56.</span><cite>Wang S.S.Y., Jie Y.E., Cheng S.W., Ling G.L., Ming H.V.Y. PARP Inhibitors in Breast and Ovarian Cancer. Cancers. 2023;15:2357.  doi: 10.3390/cancers15082357.</cite> [<a href="https://doi.org/10.3390/cancers15082357" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10137187/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37190285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=PARP%20Inhibitors%20in%20Breast%20and%20Ovarian%20Cancer&amp;author=S.S.Y.%20Wang&amp;author=Y.E.%20Jie&amp;author=S.W.%20Cheng&amp;author=G.L.%20Ling&amp;author=H.V.Y.%20Ming&amp;volume=15&amp;publication_year=2023&amp;pages=2357&amp;pmid=37190285&amp;doi=10.3390/cancers15082357&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B57-ijms-25-10876">
<span class="label">57.</span><cite>Anjali K., Singh D., Kumar P., Kumar T., Narayan G., Singh S. PARP1 Rs1136410 (A/G) Polymorphism Is Associated with Early Age of Onset of Gallbladder Cancer. Eur. J. Cancer Prev. 2022;31:311–317. doi: 10.1097/CEJ.0000000000000708.</cite> [<a href="https://doi.org/10.1097/CEJ.0000000000000708" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34406176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Cancer%20Prev.&amp;title=PARP1%20Rs1136410%20(A/G)%20Polymorphism%20Is%20Associated%20with%20Early%20Age%20of%20Onset%20of%20Gallbladder%20Cancer&amp;author=K.%20Anjali&amp;author=D.%20Singh&amp;author=P.%20Kumar&amp;author=T.%20Kumar&amp;author=G.%20Narayan&amp;volume=31&amp;publication_year=2022&amp;pages=311-317&amp;pmid=34406176&amp;doi=10.1097/CEJ.0000000000000708&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B58-ijms-25-10876">
<span class="label">58.</span><cite>Li H., Zha Y., Du F., Liu J., Li X., Zhao X. Contributions of PARP-1 Rs1136410 C&gt;T Polymorphism to the Development of Cancer. J. Cell. Mol. Med. 2020;24:14639–14644. doi: 10.1111/jcmm.16027.</cite> [<a href="https://doi.org/10.1111/jcmm.16027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7753995/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33108038/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Cell.%20Mol.%20Med.&amp;title=Contributions%20of%20PARP-1%20Rs1136410%20C&gt;T%20Polymorphism%20to%20the%20Development%20of%20Cancer&amp;author=H.%20Li&amp;author=Y.%20Zha&amp;author=F.%20Du&amp;author=J.%20Liu&amp;author=X.%20Li&amp;volume=24&amp;publication_year=2020&amp;pages=14639-14644&amp;pmid=33108038&amp;doi=10.1111/jcmm.16027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B59-ijms-25-10876">
<span class="label">59.</span><cite>Ma X.-B., Wang X.-J., Wang M., Dai Z.-M., Jin T.-B., Liu X.-H., Kang H.-F., Lin S., Xu P., Dai Z.-J. Impact of the PARP1 Rs1136410 and Rs3219145 Polymorphisms on Susceptibility and Clinicopathologic Features of Breast Cancer in a Chinese Population. Transl. Cancer Res. 2016;5 doi: 10.21037/tcr.2016.09.01.</cite> [<a href="https://doi.org/10.21037/tcr.2016.09.01" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl.%20Cancer%20Res.&amp;title=Impact%20of%20the%20PARP1%20Rs1136410%20and%20Rs3219145%20Polymorphisms%20on%20Susceptibility%20and%20Clinicopathologic%20Features%20of%20Breast%20Cancer%20in%20a%20Chinese%20Population&amp;author=X.-B.%20Ma&amp;author=X.-J.%20Wang&amp;author=M.%20Wang&amp;author=Z.-M.%20Dai&amp;author=T.-B.%20Jin&amp;volume=5&amp;publication_year=2016&amp;doi=10.21037/tcr.2016.09.01&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B60-ijms-25-10876">
<span class="label">60.</span><cite>Postawski K., Monist M., Keith G. PARP-1 Activity in Normal and Cancerous Human Endometrium and Its Relationship with Quantity of Abasic Sites (AP) Ginekol. Pol. 2011;82:16–21.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/21469519/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ginekol.%20Pol.&amp;title=PARP-1%20Activity%20in%20Normal%20and%20Cancerous%20Human%20Endometrium%20and%20Its%20Relationship%20with%20Quantity%20of%20Abasic%20Sites%20(AP)&amp;author=K.%20Postawski&amp;author=M.%20Monist&amp;author=G.%20Keith&amp;volume=82&amp;publication_year=2011&amp;pages=16-21&amp;pmid=21469519&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B61-ijms-25-10876">
<span class="label">61.</span><cite>Zhang X., Lu X., Akhter S., Georgescu M.-M., Legerski R.J. FANCI Is a Negative Regulator of Akt Activation. Cell Cycle. 2016;15:1134–1143. doi: 10.1080/15384101.2016.1158375.</cite> [<a href="https://doi.org/10.1080/15384101.2016.1158375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4889286/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27097374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Cycle&amp;title=FANCI%20Is%20a%20Negative%20Regulator%20of%20Akt%20Activation&amp;author=X.%20Zhang&amp;author=X.%20Lu&amp;author=S.%20Akhter&amp;author=M.-M.%20Georgescu&amp;author=R.J.%20Legerski&amp;volume=15&amp;publication_year=2016&amp;pages=1134-1143&amp;pmid=27097374&amp;doi=10.1080/15384101.2016.1158375&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B62-ijms-25-10876">
<span class="label">62.</span><cite>Cai Z., Duan Y., Li W., Liu Z., Gong Z., Hong S., He X., Xuanyuan X., Chen Y., Bi X., et al.  FANCI Serve as a Prognostic Biomarker Correlated with Immune Infiltrates in Skin Cutaneous Melanoma. Front. Immunol. 2023;14:1295831.  doi: 10.3389/fimmu.2023.1295831.</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1295831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10703153/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38077326/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Immunol.&amp;title=FANCI%20Serve%20as%20a%20Prognostic%20Biomarker%20Correlated%20with%20Immune%20Infiltrates%20in%20Skin%20Cutaneous%20Melanoma&amp;author=Z.%20Cai&amp;author=Y.%20Duan&amp;author=W.%20Li&amp;author=Z.%20Liu&amp;author=Z.%20Gong&amp;volume=14&amp;publication_year=2023&amp;pages=1295831&amp;pmid=38077326&amp;doi=10.3389/fimmu.2023.1295831&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B63-ijms-25-10876">
<span class="label">63.</span><cite>Fierheller C.T., Alenezi W.M., Serruya C., Revil T., Amuzu S., Bedard K., Subramanian D.N., Fewings E., Bruce J.P., Prokopec S., et al.  Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. Genes. 2023;14:277.  doi: 10.3390/genes14020277.</cite> [<a href="https://doi.org/10.3390/genes14020277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9956348/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36833203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes&amp;title=Molecular%20Genetic%20Characteristics%20of%20FANCI,%20a%20Proposed%20New%20Ovarian%20Cancer%20Predisposing%20Gene&amp;author=C.T.%20Fierheller&amp;author=W.M.%20Alenezi&amp;author=C.%20Serruya&amp;author=T.%20Revil&amp;author=S.%20Amuzu&amp;volume=14&amp;publication_year=2023&amp;pages=277&amp;pmid=36833203&amp;doi=10.3390/genes14020277&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B64-ijms-25-10876">
<span class="label">64.</span><cite>Fierheller C.T., Guitton-Sert L., Alenezi W.M., Revil T., Oros K.K., Gao Y., Bedard K., Arcand S.L., Serruya C., Behl S., et al.  A Functionally Impaired Missense Variant Identified in French Canadian Families Implicates FANCI as a Candidate Ovarian Cancer-Predisposing Gene. Genome Med. 2021;13:186. doi: 10.1186/s13073-021-00998-5.</cite> [<a href="https://doi.org/10.1186/s13073-021-00998-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8642877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34861889/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Med.&amp;title=A%20Functionally%20Impaired%20Missense%20Variant%20Identified%20in%20French%20Canadian%20Families%20Implicates%20FANCI%20as%20a%20Candidate%20Ovarian%20Cancer-Predisposing%20Gene&amp;author=C.T.%20Fierheller&amp;author=L.%20Guitton-Sert&amp;author=W.M.%20Alenezi&amp;author=T.%20Revil&amp;author=K.K.%20Oros&amp;volume=13&amp;publication_year=2021&amp;pages=186&amp;pmid=34861889&amp;doi=10.1186/s13073-021-00998-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B65-ijms-25-10876">
<span class="label">65.</span><cite>Zhang Y., Hunter T. Roles of Chk1 in Cell Biology and Cancer Therapy. Int. J. Cancer. 2014;134:1013–1023. doi: 10.1002/ijc.28226.</cite> [<a href="https://doi.org/10.1002/ijc.28226" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3852170/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23613359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Cancer&amp;title=Roles%20of%20Chk1%20in%20Cell%20Biology%20and%20Cancer%20Therapy&amp;author=Y.%20Zhang&amp;author=T.%20Hunter&amp;volume=134&amp;publication_year=2014&amp;pages=1013-1023&amp;pmid=23613359&amp;doi=10.1002/ijc.28226&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B66-ijms-25-10876">
<span class="label">66.</span><cite>McNeely S., Beckmann R., Bence Lin A.K. CHEK Again: Revisiting the Development of CHK1 Inhibitors for Cancer Therapy. Pharmacol. Ther. 2014;142:1–10. doi: 10.1016/j.pharmthera.2013.10.005.</cite> [<a href="https://doi.org/10.1016/j.pharmthera.2013.10.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24140082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacol.%20Ther.&amp;title=CHEK%20Again:%20Revisiting%20the%20Development%20of%20CHK1%20Inhibitors%20for%20Cancer%20Therapy&amp;author=S.%20McNeely&amp;author=R.%20Beckmann&amp;author=A.K.%20Bence%20Lin&amp;volume=142&amp;publication_year=2014&amp;pages=1-10&amp;pmid=24140082&amp;doi=10.1016/j.pharmthera.2013.10.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B67-ijms-25-10876">
<span class="label">67.</span><cite>Fadaka A.O., Bakare O.O., Sibuyi N.R.S., Klein A. Gene Expression Alterations and Molecular Analysis of CHEK1 in Solid Tumors. Cancers. 2020;12:662.  doi: 10.3390/cancers12030662.</cite> [<a href="https://doi.org/10.3390/cancers12030662" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7139733/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32178478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Gene%20Expression%20Alterations%20and%20Molecular%20Analysis%20of%20CHEK1%20in%20Solid%20Tumors&amp;author=A.O.%20Fadaka&amp;author=O.O.%20Bakare&amp;author=N.R.S.%20Sibuyi&amp;author=A.%20Klein&amp;volume=12&amp;publication_year=2020&amp;pages=662&amp;pmid=32178478&amp;doi=10.3390/cancers12030662&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B68-ijms-25-10876">
<span class="label">68.</span><cite>Neizer-Ashun F., Bhattacharya R. Reality CHEK: Understanding the Biology and Clinical Potential of CHK1. Cancer Lett. 2021;497:202–211. doi: 10.1016/j.canlet.2020.09.016.</cite> [<a href="https://doi.org/10.1016/j.canlet.2020.09.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32991949/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett.&amp;title=Reality%20CHEK:%20Understanding%20the%20Biology%20and%20Clinical%20Potential%20of%20CHK1&amp;author=F.%20Neizer-Ashun&amp;author=R.%20Bhattacharya&amp;volume=497&amp;publication_year=2021&amp;pages=202-211&amp;pmid=32991949&amp;doi=10.1016/j.canlet.2020.09.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B69-ijms-25-10876">
<span class="label">69.</span><cite>Morden C.R., Farrell A.C., Sliwowski M., Lichtensztejn Z., Altman A.D., Nachtigal M.W., McManus K.J. Chromosome Instability Is Prevalent and Dynamic in High-Grade Serous Ovarian Cancer Patient Samples. Gynecol. Oncol. 2021;161:769–778. doi: 10.1016/j.ygyno.2021.02.038.</cite> [<a href="https://doi.org/10.1016/j.ygyno.2021.02.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33714608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.&amp;title=Chromosome%20Instability%20Is%20Prevalent%20and%20Dynamic%20in%20High-Grade%20Serous%20Ovarian%20Cancer%20Patient%20Samples&amp;author=C.R.%20Morden&amp;author=A.C.%20Farrell&amp;author=M.%20Sliwowski&amp;author=Z.%20Lichtensztejn&amp;author=A.D.%20Altman&amp;volume=161&amp;publication_year=2021&amp;pages=769-778&amp;pmid=33714608&amp;doi=10.1016/j.ygyno.2021.02.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B70-ijms-25-10876">
<span class="label">70.</span><cite>Creasman W.J. Announcement, FIGO Stages 1988, Revisions. Gynecol. Oncol. 1989;35:125–127.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.&amp;title=Announcement,%20FIGO%20Stages%201988,%20Revisions&amp;author=W.J.%20Creasman&amp;volume=35&amp;publication_year=1989&amp;pages=125-127&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B71-ijms-25-10876">
<span class="label">71.</span><cite>Mehra P., Aditi S., Prasad K.M., Bariar N.K. Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center. Cureus. 2023;15:e38273. doi: 10.7759/cureus.38273.</cite> [<a href="https://doi.org/10.7759/cureus.38273" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10225821/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37255899/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cureus&amp;title=Histomorphological%20Analysis%20of%20Ovarian%20Neoplasms%20According%20to%20the%202020%20WHO%20Classification%20of%20Ovarian%20Tumors:%20A%20Distribution%20Pattern%20in%20a%20Tertiary%20Care%20Center&amp;author=P.%20Mehra&amp;author=S.%20Aditi&amp;author=K.M.%20Prasad&amp;author=N.K.%20Bariar&amp;volume=15&amp;publication_year=2023&amp;pages=e38273&amp;pmid=37255899&amp;doi=10.7759/cureus.38273&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B72-ijms-25-10876">
<span class="label">72.</span><cite>Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting Results of Cancer Treatment. Cancer. 1981;47:207–214. doi: 10.1002/1097-0142(19810101)47:1&amp;#x0003c;207::AID-CNCR2820470134&amp;#x0003e;3.0.CO;2-6.</cite> [<a href="https://doi.org/10.1002/1097-0142(19810101)47:1&amp;#x0003c;207::AID-CNCR2820470134&amp;#x0003e;3.0.CO;2-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7459811/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Reporting%20Results%20of%20Cancer%20Treatment&amp;author=A.B.%20Miller&amp;author=B.%20Hoogstraten&amp;author=M.%20Staquet&amp;author=A.%20Winkler&amp;volume=47&amp;publication_year=1981&amp;pages=207-214&amp;pmid=7459811&amp;doi=10.1002/1097-0142(19810101)47:1&amp;#x0003c;207::AID-CNCR2820470134&amp;#x0003e;3.0.CO;2-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B73-ijms-25-10876">
<span class="label">73.</span><cite>Woroniecka R., Rymkiewicz G., Szafron L.M., Blachnio K., Szafron L.A., Bystydzienski Z., Pienkowska-Grela B., Borkowska K., Rygier J., Kotyl A., et al.  Cryptic MYC Insertions in Burkitt Lymphoma: New Data and a Review of the Literature. PLoS ONE. 2022;17:e0263980.  doi: 10.1371/journal.pone.0263980.</cite> [<a href="https://doi.org/10.1371/journal.pone.0263980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8846522/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35167621/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Cryptic%20MYC%20Insertions%20in%20Burkitt%20Lymphoma:%20New%20Data%20and%20a%20Review%20of%20the%20Literature&amp;author=R.%20Woroniecka&amp;author=G.%20Rymkiewicz&amp;author=L.M.%20Szafron&amp;author=K.%20Blachnio&amp;author=L.A.%20Szafron&amp;volume=17&amp;publication_year=2022&amp;pages=e0263980&amp;pmid=35167621&amp;doi=10.1371/journal.pone.0263980&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B74-ijms-25-10876">
<span class="label">74.</span><cite>McLaren W., Gil L., Hunt S.E., Riat H.S., Ritchie G.R.S., Thormann A., Flicek P., Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.  doi: 10.1186/s13059-016-0974-4.</cite> [<a href="https://doi.org/10.1186/s13059-016-0974-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4893825/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27268795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Biol.&amp;title=The%20Ensembl%20Variant%20Effect%20Predictor&amp;author=W.%20McLaren&amp;author=L.%20Gil&amp;author=S.E.%20Hunt&amp;author=H.S.%20Riat&amp;author=G.R.S.%20Ritchie&amp;volume=17&amp;publication_year=2016&amp;pages=122&amp;pmid=27268795&amp;doi=10.1186/s13059-016-0974-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B75-ijms-25-10876">
<span class="label">75.</span><cite>Calculated Consequences.  [(accessed on 3 July 2021)].  Available online:  <a href="https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html</a>.</cite>
</li>
<li id="B76-ijms-25-10876">
<span class="label">76.</span><cite>Gerds T.A., Cai T., Schumacher M. The Performance of Risk Prediction Models. Biom. J. 2008;50:457–479. doi: 10.1002/bimj.200810443.</cite> [<a href="https://doi.org/10.1002/bimj.200810443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18663757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biom.%20J.&amp;title=The%20Performance%20of%20Risk%20Prediction%20Models&amp;author=T.A.%20Gerds&amp;author=T.%20Cai&amp;author=M.%20Schumacher&amp;volume=50&amp;publication_year=2008&amp;pages=457-479&amp;pmid=18663757&amp;doi=10.1002/bimj.200810443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/11507582/bin/ijms-25-10876-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">ijms-25-10876-s001.zip</a><sup> (12MB, zip) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All data are available in the main text or <a href="#app1-ijms-25-10876" class="usa-link">Supplementary Materials</a>.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from International Journal of Molecular Sciences are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/ijms252010876"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/ijms-25-10876.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (13.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11507582/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11507582/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11507582%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507582/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11507582/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11507582/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/39456660/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11507582/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/39456660/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11507582/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11507582/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="58jKOZHq6GSrJDxbigqOE179P3YmTlkDHiJXARaYnomLUJ2cyfOob90PWVnzW6P8">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
